FAR FROM A SCAM BROTHER.....As a lifetime K.C. fan I'm ashamed of you for posting that Tyreek, but you sure have some speed and hands. You can make up for it if you buy all the shares on the ask tomorrow and Tuesday!
AFTER 10:00 Eastern time please, I still have some loading to do!
Here's some info for you to brush up on.......
Long term Pctl DD library update 8/15/2020 DD & links & for U.K. & CANADA Consolidated, Annihilyzer in action
========================== DesertEagle Saturday, 08/15/20 01:06:56 AM Re: None 0
Post # of 125226
It doesn't take a rocket scientist...
to figure out where PCT Ltd is heading and why the Q1 was average and each subsequent Q will be much better. As the saying goes, a picture is worth a thousand words...
1. PCT LTD Increases Fluid Capacity, Hires New Design Engineer, Ramps Up Midwest Fulfillment Capabilities. 2. PCT LTD Announces Receipts of New Purchase Orders for Annihilyzer Infection Control Systems in NYC Hospitals. 3. PCT LTD Reports Q3 2019 Financials; Revenue Increases 435%, Operating Expenses Decrease 4. PCT EUROPE LTD Signs Distribution Agreement with UK NHS Company, Receives Additional NYC Hospital Orders. 5. PCT LTD Discusses Its Rapid Growth and Expansion Plans. 6. PCT LTD Continues Accelerated Expansion with New Hospital Installations and Fluids Distributors. 7. PCT LTD Formalizes Agreement with PCT EUROPE and Provides Update on Current Business Operations. 8. PCT LTD Adds Additional Distributors, Announces New Hospital Installations and Provides Shareholder Update. 9. PCT LTD Discusses the Increasing Demand for Disinfecting Solutions. 10. PCT LTD Provides Update to Public, Distributors and Sub-Registrants Regarding Use of Products. 11. PCT LTD Provides Update on 2019 10-K Filing, Highlights Revenue Growth, Expense Decrease. 12. PCT LTD Provides Update on US Healthcare Related Activities. 13. PCT LTD Provides Update of Authorized Distributors and Supplemental Registrants.
When the "STOP" comes off and the Q2 comes out we go from Dip to Rip... that is my projection.
Updated list as of 8/14/20 of businesses using PCT Ltd. fluids in some part of their product line. With yesterday's PR I changed the format. I listed by level and retail. I have a separate listing for Seriously clean bc their to big.
PCTL level 2 and 3 distributors/ fluid manufactures with EPA Registrations by year registered off the EPA site
Year Registered 2014 PCT LTD. EXCELYTE VET Hydrolyte vetrinox 92108-1 registered 2/6/2014
Year registered 2018 DANOLYTE DANOLYTE GLOBAL, INC. 92108-1-91582 Registered 2/13/2018 Bio Blasting BIOBLAST DISINFECTANT 92108-1-91707 Registered 9/12/2018
Year Registered 2019 Seriously Clean CuraClean Disinfectant/Sanitizer GROW WASH RX GRUNGEWASH RX HOCL SOLUTIONS DISINFECTANT/SANITIZER NIXALL DISINFECTANT/SANITIZER PURE & CLEAN DISINFECTANT/SANITIZER PURE & CLEAN SPORTS DISINFECTANT/SANITIZER 92108-1-88098 Registered 12/9/2019
Currently there are 225 NHS Trusts in the United Kingdom and anyone who knows how the social healthcare systems work knows that once one trust comes on board, the rest will normally follow suit.
One or two trusts doesn't sound like much to someone that doesn't understand how the system works, but each one of those is responsible for the approval and purchasing of equipment for multiple hospitals, clinics and long term care facilities.
As an example, Northumbria Healthcare NHS Foundation Trust manages 14 Hospitals and Clinics and North Tees and Hartlepool NHS Foundation Trust manages 17 Hospitals and Clinics. And those 31 Hospitals and Clinics do not represent the Long Term Care facilities under their control as well.
As many people like "Facts not Fiction" and "Proof", the below list represents the current Trusts operating in the United Kingdom...
Airedale NHS Foundation Trust Alder Hey Children's NHS Foundation Trust Ashford and St Peter's Hospitals NHS Foundation Trust Avon and Wiltshire Mental Health Partnership NHS Trust Barking, Havering and Redbridge University Hospitals NHS Trust Barnet, Enfield and Haringey Mental Health NHS Trust Barnsley Hospital NHS Foundation Trust Barts Health NHS Trust Bedford Hospital NHS Trust Berkshire Healthcare NHS Foundation Trust Birmingham and Solihull Mental Health NHS Foundation Trust Birmingham Community Healthcare NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Black Country Healthcare NHS Foundation Trust Blackpool Teaching Hospitals NHS Foundation Trust Bolton NHS Foundation Trust Bradford District NHS Foundation Trust Bradford Teaching Hospitals NHS Foundation Trust Bridgewater Community Healthcare NHS Foundation Trust Brighton and Sussex University Hospitals NHS Trust Buckinghamshire Healthcare NHS Trust Burton Hospitals NHS Foundation Trust Calderdale and Huddersfield NHS Foundation Trust Cambridge University Hospitals NHS Foundation Trust Cambridgeshire and Peterborough NHS Foundation Trust Cambridgeshire Community Services NHS Trust Camden and Islington NHS Foundation Trust Central and North West London NHS Foundation Trust Central London Community Healthcare NHS Trust Chelsea and Westminster Hospital NHS Foundation Trust Cheshire and Wirral Partnership NHS Foundation Trust Chesterfield Royal Hospital NHS Foundation Trust City Hospitals Sunderland NHS Foundation Trust Cornwall Partnership NHS Foundation Trust Countess Of Chester Hospital NHS Foundation Trust County Durham and Darlington NHS Foundation Trust Coventry and Warwickshire Partnership NHS Trust Croydon Health Services NHS Trust Cumbria Northumberland Tyne and Wear NHS Foundation Trust Dartford and Gravesham NHS Trust Derbyshire Community Health Services NHS Foundation Trust Derbyshire Healthcare NHS Foundation Trust Devon Partnership NHS Trust Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust Dorset County Hospital NHS Foundation Trust Dorset Healthcare University NHS Foundation Trust Dudley and Walsall Mental Health Partnership NHS Trust East and North Hertfordshire NHS Trust East Cheshire NHS Trust East Kent Hospitals University NHS Foundation Trust East Lancashire Hospitals NHS Trust East London NHS Foundation Trust East Midlands Ambulance Service NHS Trust East Of England Ambulance Service NHS Trust East Suffolk and North Essex NHS Foundation Trust East Sussex Healthcare NHS Trust Epsom and St Helier University Hospitals NHS Trust Essex Partnership University NHS Foundation Trust Frimley Health NHS Foundation Trust Gateshead Health NHS Foundation Trust George Eliot Hospital NHS Trust Gloucestershire Care Services NHS Trust Gloucestershire Health and Care NHS Foundation Trust Gloucestershire Hospitals NHS Foundation Trust Great Ormond Street Hospital for Children NHS Foundation Trust Great Western Hospitals NHS Foundation Trust Greater Manchester Mental Health NHS Foundation Trust Guy's and St Thomas' NHS Foundation Trust Hampshire Hospitals NHS Foundation Trust Harrogate and District NHS Foundation Trust Hertfordshire Community NHS Trust Hertfordshire Partnership University NHS Foundation Trust Homerton University Hospital NHS Foundation Trust Hounslow and Richmond Community Healthcare NHS Trust Hull University Teaching Hospitals NHS Trust Humber Teaching NHS Foundation Trust Imperial College Healthcare NHS Trust Isle Of Wight NHS Trust James Paget University Hospitals NHS Foundation Trust Kent and Medway NHS and Social Care Partnership Trust Kent Community Health NHS Foundation Trust Kettering General Hospital NHS Foundation Trust King's College Hospital NHS Foundation Trust Kingston Hospital NHS Foundation Trust Lancashire & South Cumbria NHS Foundation Trust Lancashire Teaching Hospitals NHS Foundation Trust Leeds and York Partnership NHS Foundation Trust Leeds Community Healthcare NHS Trust Leeds Teaching Hospitals NHS Trust Lewisham and Greenwich NHS Trust Lincolnshire Community Health Services NHS Trust Lincolnshire Partnership NHS Foundation Trust Liverpool Heart and Chest NHS Foundation Trust Liverpool University Hospitals NHS Foundation Trust Liverpool Women's NHS Foundation Trust London Ambulance Service NHS Trust London North West University Healthcare NHS Trust Luton and Dunstable University Hospital NHS Foundation Trust Maidstone and Tunbridge Wells NHS Trust Manchester University NHS Foundation Trust Medway NHS Foundation Trust Mersey Care NHS Foundation Trust Mid and south Essex Foundation Trust Mid Cheshire Hospitals NHS Foundation Trust Mid Yorkshire Hospitals NHS Trust Midlands Partnership NHS Foundation Trust Milton Keynes University Hospital NHS Foundation Trust Moorfields Eye Hospital NHS Foundation Trust Norfolk and Norwich University Hospitals NHS Foundation Trust Norfolk and Suffolk NHS Foundation Trust Norfolk Community Health and Care NHS Trust North Bristol NHS Trust North Cumbria Integrated Care NHS Foundation Trust North Cumbria University Hospitals NHS Trust North East Ambulance Service NHS Foundation Trust North East London NHS Foundation Trust North Middlesex University Hospital NHS Trust North Staffordshire Combined Healthcare NHS Trust North Tees and Hartlepool NHS Foundation Trust North West Ambulance Service NHS Trust North West Anglia NHS Foundation Trust North West Boroughs Healthcare NHS Foundation Trust Northampton General Hospital NHS Trust Northamptonshire Healthcare NHS Foundation Trust Northern Devon Healthcare NHS Trust Northern Lincolnshire and Goole NHS Foundation Trust Northumbria Healthcare NHS Foundation Trust Nottingham University Hospitals NHS Trust Nottinghamshire Healthcare NHS Foundation Trust Oxford Health NHS Foundation Trust Oxford University Hospitals NHS Foundation Trust Oxleas NHS Foundation Trust Pennine Acute Hospitals NHS Trust Pennine Care NHS Foundation Trust Poole Hospital NHS Foundation Trust Portsmouth Hospitals NHS Trust Project Nightingale NHS Trust Queen Victoria Hospital NHS Foundation Trust Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust Rotherham Doncaster and South Humber NHS Foundation Trust Royal Berkshire NHS Foundation Trust Royal Brompton and Harefield NHS Foundation Trust Royal Cornwall Hospitals NHS Trust Royal Devon and Exeter NHS Foundation Trust Royal Free London NHS Foundation Trust Royal National Orthopaedic Hospital NHS Trust Royal Papworth Hospital NHS Foundation Trust Royal Surrey NHS Foundation Trust Royal United Hospitals Bath NHS Foundation Trust Salford Royal NHS Foundation Trust Salisbury NHS Foundation Trust Sandwell and West Birmingham Hospitals NHS Trust Sheffield Children's NHS Foundation Trust Sheffield Health and Social Care NHS Foundation Trust Sheffield Teaching Hospitals NHS Foundation Trust Sherwood Forest Hospitals NHS Foundation Trust Shrewsbury and Telford Hospital NHS Trust Shropshire Community Health NHS Trust Solent NHS Trust Somerset Partnership NHS Foundation Trust South Central Ambulance Service NHS Foundation Trust South East Coast Ambulance Service NHS Foundation Trust South London and Maudsley NHS Foundation Trust South Tees Hospitals NHS Foundation Trust South Tyneside And Sunderland NHS Foundation Trust South Tyneside NHS Foundation Trust South Warwickshire NHS Foundation Trust South West London and St George's Mental Health NHS Trust South West Yorkshire Partnership NHS Foundation Trust South Western Ambulance Service NHS Foundation Trust Southern Health NHS Foundation Trust Southport and Ormskirk Hospital NHS Trust St George's University Hospitals NHS Foundation Trust St Helens and Knowsley Hospitals NHS Trust Stockport NHS Foundation Trust Surrey and Borders Partnership NHS Foundation Trust Surrey and Sussex Healthcare NHS Trust Sussex Community NHS Foundation Trust Sussex Partnership NHS Foundation Trust Tameside Hospital NHS Foundation Trust Taunton and Somerset NHS Foundation Trust Tavistock and Portman NHS Foundation Trust Tees, Esk and Wear Valleys NHS Foundation Trust The Christie NHS Foundation Trust The Clatterbridge Cancer Centre NHS Foundation Trust The Dudley Group NHS Foundation Trust The Hillingdon Hospitals NHS Foundation Trust The Newcastle Upon Tyne Hospitals NHS Foundation Trust The Princess Alexandra Hospital NHS Trust The Queen Elizabeth Hospital, King's Lynn. NHS Foundation Trust The Rotherham NHS Foundation Trust The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust The Royal Marsden NHS Foundation Trust The Royal Orthopaedic Hospital NHS Foundation Trust The Royal Wolverhampton NHS Trust The Walton Centre NHS Foundation Trust Torbay and South Devon NHS Foundation Trust United Lincolnshire Hospitals NHS Trust University College London Hospitals NHS Foundation Trust University Hospital of Derby and Burton NHS Foundation Trust University Hospital Southampton NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust University Hospitals Coventry and Warwickshire NHS Trust University Hospitals Of Leicester NHS Trust University Hospitals Of Morecambe Bay NHS Foundation Trust University Hospitals of North Midlands University Hospitals Plymouth NHS Trust Walsall Healthcare NHS Trust Warrington and Halton Hospitals NHS Foundation Trust West Hertfordshire Hospitals NHS Trust West London NHS Trust West Midlands Ambulance Service University NHS Foundation Trust West Suffolk NHS Foundation Trust Western Sussex Hospitals NHS Foundation Trust Whittington Health NHS Trust Wirral Community NHS Foundation Trust Wirral University Teaching Hospital NHS Foundation Trust Worcestershire Acute Hospitals NHS Trust Worcestershire Health and Care NHS Trust Wrightington, Wigan and Leigh NHS Foundation Trust Wye Valley NHS Trust Yeovil District Hospital NHS Foundation Trust York Teaching Hospital NHS Foundation Trust Yorkshire Ambulance Service NHS Trust
Now when people tell you that PCTL getting their foot into the door of the NHS system isn't a big deal, you can tell them you know better.
DE
aandt Saturday, August 1, 2020 9:32:43 AM Re: None Post # of 122844 Repur/Collaborative Technologies
Looks like they will be in the food industry, they were just approved by the USDA and added to the NSF (National Sanitation Foundation) list. https://info.nsf.org/USDA/Listings.asp (search for RePur).
Egold Monday, July 27, 2020 1:48:03 PM Re: None Post # of 121773 New updated list Looks a lot better. Stick this one if ya want
Updated list as of 7/27/20 of businesses using PCT Ltd. fluids in some part of their product line. PCTL level 2 and 3 distributors/ fluid manufactures with EPA Registrations by year registered
Year Registered 2014 PCT LTD. EXCELYTE VET Hydrolyte vetrinox 92108-1 registered 2/6/2014
Year registered 2018 DANOLYTE DANOLYTE GLOBAL, INC. 92108-1-91582 Registered 2/13/2018 Bio Blasting BIOBLAST DISINFECTANT 92108-1-91707 Registered 9/12/2018 Bio Blasting BIOBLAST DISINFECTANT KYUNG NONG CORPORATION S. Korea 92108-1-91707 Registered 9/12/2018
Vision source Vision Source has over 3,300 locally owned optometry practices. Each one could carry Pure and Clean's products. https://visionsource.com/vendors/ Pure and Clean's website for Vision source https://pncvision.com/
Lots of interesting info. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315945/ J Oral Maxillofac Surg. 2020 Jun 25 doi: 10.1016/j.joms.2020.06.029 [Epub ahead of print] PMCID: PMC7315945 PMID: 32653307 Hypochlorous Acid: A Review Michael S. Block, DMD** and Brian G. Rowan, DMD, MD† includes, for example: Quote:
Abstract The surgeon needs to have an inexpensive, available, nontoxic, and practical disinfectant that is effective in sanitizing against the COVID-19 (Coronavirus Disease 2019) virus. The purpose of this article was to review the evidence for using hypochlorous acid in the office setting on a daily basis. The method used to assemble recommendations was a review of the literature including evidence for this solution when used in different locations and industries other than the oral-maxillofacial clinic facility. The results indicate that this material can be used with a high predictability for disinfecting against the COVID-19 (Coronavirus Disease 2019) virus.
Quote:
Stability of Solution Rossi-Fedele et al35 investigated the shelf life of HOCl by being either exposed to or protected from sunlight. When the HOCl solution was exposed to sunlight, the chlorine reduction started on day 4. When it was sheltered from sunlight, the chlorine reduction started after day 14. The half-life increases with decreasing pH owing to the decreasing ratio of OCl–to HOCl.36 The parts per million (ppm) is the concentration of the –OCl, which is the active ingredient and is known as the available free chlorine (AFC) in the solution. HOCl solutions are less stable when exposed to UV radiation, sunlight, or contact with air or when the temperature of the solution is elevated greater than 25°C. HOCl solutions should be stored in cool, dark places, and contact with air should be minimized. The water for fabrication should be water that contains organic and inorganic ion concentrations that are as small as possible.37, 38, 39, 40
Concentration Related to Time Needed for Virucidal Action HOCl has been shown to inactivate a variety of viruses including coronaviruses in less than 1 minute.39 At a concentration of 200 ppm, HOCl is effective in decontaminating inert surfaces carrying noroviruses and other enteric viruses in a 1-minute contact time. When diluted 10-fold, HOCl solutions at 20 ppm were still effective in decontaminating environmental surfaces carrying viruses in a 10-minute contact time.
Quote:
Discussion The coronavirus pandemic has caused both a massive health care and economic disruption across the world. The current unavailability of an effective antiviral drug or approved vaccine means that the implementation of effective preventive measures is necessary to counteract COVID-19. Oral-maxillofacial surgeons are high-risk providers providing needed care to patients. As more OMS and surgical offices open during reopening in the United States and elsewhere in the world, the need to reduce the risk of transmission of COVID-19 between patients and providers is necessary. It is widely believed that with proper screening and discretion, along with adequate personal protective equipment, there is a low probability of becoming infected. The goal of this article is to provide information regarding disinfection in the clinical office setting using HOCl, a relatively inexpensive, nontoxic, noncorrosive, and well-studied compound.
HOCl has uses in many industries from farming and restaurants, regarding food, to health care applications, including chronic wound care and disinfection.34 , 36 , 43 , 45 , 46 , 63 In addition to the use of HOCl as a liquid-based disinfectant, fogging with hypochlorous vapor has shown virucidal activity against numerous types of viruses and bacteria.40 , 56 , 57 This is of potential benefit to disinfect large spaces such as medical and dental offices where aerosols can be airborne for extended periods.42 , 44 , 64 In terms of particle size, oral-maxillofacial surgeons may be at a slightly lower risk than their dental counterparts because ultrasonic scaling and high-speed handpieces create smaller particles that remain airborne longer.42 However, aerosols are still created with surgical handpieces. Additionally, the COVID-19 virus can be present on some surfaces for days, and the disinfection of all surfaces of an operatory is important to reduce transmission.9 , 10
Many properties of HOCl contribute to why it may be the disinfectant of choice in the OMS setting. Although the shelf life of HOCl is relatively short, it is effective for up to 2 weeks under ideal conditions.35 It can be made on-site inexpensively. A gallon of HOCl can be purchased from manufacturers but it is far more economical for an oral-maxillofacial surgeon to produce the solution on-site in the office.65 A variety of HOCl systems costing less than $275 are available on the market.66 By combining non-iodinated salt, water, and electricity,33 1 L of HOCl can be made in 8 minutes and the process can be repeated many times throughout the day. By comparison, a pack of common disinfecting wipes containing quaternary ammonium compounds costs between $4 and $15 for a pack containing 80 sheets. These wipes may only last a day or two depending the size of the office and area to clean. Shortages of these products can occur, making sourcing them difficult as well.67
In addition to using HOCl in the form of wipes for disinfecting, using HOCl vapors through a fogging machine is an economical way to disinfect a large operating room or suite in which aerosols were produced during surgery. Foggers or misting machines are handheld machines and can be purchased for a reasonable cost.68 The aerosol mist ideally should be less than 20 µm in size to maximally disinfect an area. It is important to note that the fogging process can alter the physical and chemical properties of the disinfectant, making it more dilute and basic. As mentioned before, the AFC concentration can be reduced by approximately 70% and the pH can increase by about 1.3.40 To make a vapor as effective as a solution containing 100 ppm of HOCl, the solution would need to be concentrated. The fine mist can be left in the empty surgical room without thought regarding harmful chemical effects; the surfaces are then wiped clean and dry after a few minutes and, for a more dilute solution, after 10 minutes.
HOCl is one disinfectant that, when combined with adequate personal protective equipment, screening and social-distancing techniques, hand washing, and high-volume evacuation suction, may help reduce the transmission of COVID-19 in the outpatient OMS setting. It comprises many of the desired effects of the ideal disinfectant: It is easy to use, is inexpensive, has a good safety profile, and can be used to disinfect large areas quickly and with a broad range of bactericidal and virucidal effects.
March 23, 2020 Hypochlorous acid (HClO) is recommended for hand washing and disinfecting the environment Oliver Ho, Ph.D. Candidate | Institute of Health and Welfare Policy, School of Medicine, National Yang-Ming University, Taipei, Taiwan A study published by Allison E. Aiello in 2012 (1) suggested that in the early stages of an influenza outbreak, the government should promote anti-epidemic measures to wear masks and maintain hand hygiene. The community infection caused by the COVID-19 virus caused panic among the population, which caused insufficient resources for masks and disinfectant supplies.
In Japan, research on the use of hypochlorous acid was carried out 20 years ago (2). Hypochlorous acid has a good effect in disinfection. It is not as toxic as bleach and it is not as prone to fire as alcohol. In Japan it is also used for medical, food, and workplace disinfection, including hand washing or surgery, and even as a mouthwash (2, 3). However, too high a concentration may cause damage to the skin, and too low a concentration may lack bactericidal power. If hypochlorous acid water is used on the skin, like alcohol, excessive use may cause skin allergies. The use of hypochlorous acid in environmental disinfection should be avoided on iron and rust. Hypochlorous water for environmental disinfection is 100 ppm, If sprayed directly on the hands, 30-50 ppm is recommended to avoid excessive damage to the skin. To avoid skin irritation, rinse with water after use.
References: 1. Aiello, AE, Perez, V., Coulborn, RM, Davis, BM, Uddin, M., & Monto, AS (2012). Facemasks, hand hygiene, and influenza among young adults: a randomized intervention trial. PloS one, 7 (1).
2. OKUBO, K., URAKAMI, H., & TAMURA, A. (1999). Cytotoxicity and microbicidal activity of electrolyzed strong acid water and acidic hypochlorite solution under isotonic conditions. Journal of Infectious Diseases, 73 (10).
3. Ono Tomoko. (2012). Examples of application of various germ bactericidal effects of weakly acidic hypoglycinic acid aqueous solution. Journal of the Japan Society of Pharmaceutical Industry = Journal of the Brewing Society of Japan, 107 (2), 100-109.
========================= fourfive6 Wednesday, July 22, 2020 10:15:17 AM Re: None Post # of 121147 I’m hearing some chatter re: this G2/Blackstone mashup — Y2X Life Sciences — anyone hearing anything?
This all ties back to NY Presbyterian and allegedly, a handful of their board members making introductions — I’m wondering if the PR last Friday is related?
If nothing else, nice to see the sector continue its take off — this rising tide will continue to elevate PCTL and the IP.
I am a former dairy farmer and have family members still running farms, so I also have been curious about this. Here is some research I have found. Not specific to PCTL but general to HOCL applications
After 10K 0.048-0.066 After 1st 10Q 0.065-0.127 with certain news it could go much higher to the dollar range After 2nd 10Q 0.18-0.776 with certain news it could go well over a dollar on a run
From Me: Reasons for PCTL to run...
1) The patented Annihilyzer® Infection Control System, Annihilyzer® On Site Generator and Large Volume production unit sales and leases continue to grow in 2020. PCTL is expanding to meet the increase in demand with new facilities in Fort Wayne, Indiana.
2) PCT Ltd recently announced they had reached a final agreement with Paradigm Convergence Technologies (Europe) Ltd. The agreement was enacted on May 25th, 2020 and will secure a mutually beneficial business relationship between the two entities, in which PCTL will hold a beneficial stake. This agreement opens up the United Kingdom and 5 European countries to the PCT Ltd systems. The equipment will be manufactured in the United Sates and shipped to the United Kingdom and Europe.
3) PCT Ltd continues to increase hospital installations. In a recent interview, Mr. Grieco (CEO) indicated that 3 additional installations have been completed since May 18th 2020 and he sees PCT Ltd performing an additional 2 to 3 installations per month through the rest of the year. Each one of these systems represent recurring revenue to the company.
4) PCT Ltd is adding additional distributors to continue its expansion. BOX Bioscience (www.boxbioscience.com) of Mount Pleasant, SC with operations in North Carolina was recently approved as a Level 3 distributor. Ryan Cowell, CEO of BOX Bioscience stated “We were very excited to learn of this distributorship opportunity because our business was seeking this type of high-quality source for HOCL”.
5) Although PCT Ltd is primarily focused on the development and deployment of their patented Annihilyzer® Infection Control System and Annihilyzer® On Site Generator to address the 36 Billion Dollar per year Hospital Acquired Infections market, they have quickly adapted their business model to also supply their Hydrolyte® disinfecting fluids to all parts of the country due to the surge in demand caused by the current Covid-19 pandemic.
6) PCT Ltd’s Hydrolyte® is currently listed on 6 EPA lists of registered products. List B: Products Effective Against Mycobacterium tuberculosis List C: Products Effective Against Human HIV-1 Virus List F: Products Effective Against Hepatitis C List G: Products Effective Against Norovirus List H: Products Effective Against MRSA and/or VRE List N: Products for use against SARS-CoV-2, the virus that causes COVID-19
7) PCT Ltd’s revenue continue to increase year over year. 2015: $141 2016: $113,387 2017: $123,105 2018: $266,122 2019: $534,852 (9 months ending September 30, 2019) 2020: Record Breaking
8) Due to the current Covid-19 Pandemic, the Full Year 2019 10-K has been delayed. It is expected that the Full Year 2019 10-K will be released quickly followed by the 1st Quarter 10-Q and then the 2nd Quarter 10-Q soon after that.
Because we believe these releases will happen in quick succession and show that the company is increasing revenue while decreasing debt and at the same time expanding hospital installations and distributors to meet current and future demand, we feel that a substantial run up in share price is inevitable when the company becomes current.
9) As PCT Ltd expands their footprint in the United States, United Kingdom and Europe, we expect the company to move up to the OTCQB later in 2020 and move off the OTC and on to a major exchange early in 2021.
Here is my updated list as of 7/16/20 including a few that were not on the list you are referring to. I did include NetZero since you brought them up.
Updated list as of 7/16/20 78+ businesses using PCT Ltd. fluids in some part of their product line. PCTL level 2 and 3 distributors/ fluid manufactures with EPA Registrations by year registered
Year Registered 2014 PCT LTD. EXCELYTE VET Hydrolyte vetrinox 92108-1 registered 2/6/2014
Year registered 2018 DANOLYTE DANOLYTE GLOBAL, INC. 92108-1-91582 Registered 2/13/2018 Bio Blasting BIOBLAST DISINFECTANT 92108-1-91707 Registered 9/12/2018 Bio Blasting BIOBLAST DISINFECTANT KYUNG NONG CORPORATION S. Korea 92108-1-91707 Registered 9/12/2018
Vision source Vision Source has over 3,300 locally owned optometry practices. Each one could carry Pure and Clean's products. https://visionsource.com/vendors/ Pure and Clean's website for Vision source https://pncvision.com/
And the above is missing these 5 distributors: Advanced Environmental Solutions, Inc Collaborative Technologies Llc Danolyte Global, Inc. Earth Safe Solutions, Llc Net Zero Tools Inc
I am not trying to be controversial. It seems like you appreciate that proper DD is done. I am just adding to the DD for this stock, so that the correct info is posted. If you believe there are 77 sites instead of the above 47 sites, then what are your additional 30 sites?
======================================================= falon Wednesday, July 15, 2020 9:24:50 AM Re: None Post # of 119913 The evolution of Paradigm Convergence Technologies Corporation
PCTL's successful launch of the Annihilyzer System 18 months ago leads to a system in 20% of hospitals in New York City. PCTL’s flagship product Annihililyzer was, is and will be the foundation of the company’s success moving forward.
The company was on the brink of faltering due to its growing debt and had to execute toxic financing for its survival.
Then PCTL received an unexpected gift due to unprecedented demand for HOCI because of the Covid-19 pandemic.
What the CEO did by shifting the focus to supplying HOCI due to the high demand and need, enabled PCTL to establish a more stable financial condition that it has ever seen.
There are many companies selling HOCI so to increase PCTL’s footprint the CEO increased production and brought on more distributors. The high demand for HOCI will continue in the foreseeable future however it isn’t going to last forever and competition will increase moving forward.
What has given PCTL an edge is that we were already established providing HOCI, they have a supply chain already in place and have equipment to produce large quantities of product.
ALL the other areas PCTL has business interests including oil and gas, food safety, agriculture, and cannabis to name a few should be adding to the bottom line moving forward.
There are many types of whole room disinfection systems but none like the Annihilyzer.
It is my belief that the Annihilyzer is really going to be the ultimate game changer. It is just too versatile, cost effective and provides hospitals not only with a whole room disinfection system but a second product for the price of one.
FACTS about the Annihilyzer:
The best solution to a multi-billion dollar problem.
The Most Technologically Advanced Disinfection System Ever Created to Eliminate Hospital Associated Infections (HAIs) using Patented RFID Technology for Tracking and Disinfecting Protocols.
Why is the Annihilyzer Infection Control System one of the best and most versatile in the world ?
The Annihilyzer System is truly a cost-effective Green Seal Certified end-to-end total facility disinfection and cleaning system. This system generates both a hospital grade disinfectant and a very effective cleaning solution to cover virtually all of your cleaning and disinfection needs. These on-site generators produce stable electrochemically activated solutions, OSG 460D - Hospital Grade Disinfectant that is effective against C. diff, MRSA, and VRE, and an OSG 11-12 All Purpose Cleaner, and downtime for the process is only 15 - 20 minutes with no special preparation or precautions necessary.
The Annihilyzer System doesn't stop there, though. The icing on the cake is our state-of-the-art whole-room and handheld electrostatic sprayers that make quick work of completely disinfecting a room. Our 460D disinfectant can even be used to disinfect floors without leaving a haze or residue. We use a powerful non-synthetic disinfectant along with an automated electrostatic spray cart and/or electrostatic sprayers and patented RFID tracking technology that together are unmatched the industry to ensure proper and complete application.
What can the Annihilyzer do?
Save time and money by generating disinfectant and all-purpose cleaner on-site, on-demand
Eliminate the toughest bacteria, viruses, and fungi, including C. diff, C. auris, MRSA, VRE, blood-borne pathogens, and more.
Create 'industry best' protocols and 'push' them out to your cleaning staff in real-time with the Annihilist dashboard and mobile app
Generate reports that show when the areas were cleaned, who cleaned them, and what was done
Increase staff efficiency and effectiveness with process tracking, training, and accountability
How does the Annihilyzer save companies money?
Costs associated with purchasing and managing chemicals – eliminated
Freight charges for chemical deliveries – eliminated
Chemical container disposal or recycling costs – eliminated
Personal protection gear for cleaning – eliminated
Wastewater disposal costs and related fines for non-compliance – eliminated
Workers comp claims due to chemical burns and fume inhalation – eliminated
Happier, healthier and more productive workers
Same or better cleaning power than traditional hazardous chemicals for less
Eliminates costs associated with ordering, inventorying and disposing of chemicals and containers
How many hospitals are in NYC?
There are 62 acute care hospitals in New York City.
How many hospitals in NYC have at least one Annihilyzer System?
PCTL has installed at least 14 systems and gained 22.5% market share in NYC hospitals in less than 18 months.
Most Technologically Advanced Disinfection System Ever Created Annihilyzer the future for Healthcare and other Industries
During the Coronavirus Pandemic a Hospital with the Annihilyzer in place was in a better position than a hospital without it. Many hospitals will be asking themselves what could we have done differently? If they know about the Annihilyzer, having one will certainly be one of their answers. This is not the last so they have to put themselves in the best position for future events.
What is a better investment for a whole room Infection Control System:
Annihilyzer versus an UV system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”. Also the Annihilyzer cost less than half that of one of the best UV system on the market, the Xenex “LightStrike” cost about $125,000,
Annihilyzer versus a Chemical (Hydrogen Peroxide) based system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”. Chemical based solutions require protective equipment, are more expensive and are harsh on furniture and one company called Hanosil sells their machine for under $10,000 however it costs $20 in product to clean each room.
It cost $1 in HOCI to clean a room.
================================================
DesertEagle tv debut ( this will not be active till probably end of August) will post when an interview/ or when DE’s add’s begin appearing.
——————————————— Friday, 07/10/20 01:18:54 PM Re: None 0 Post # of 119239 Updated list as of 7/10/20 77+ businesses using PCT Ltd. fluids in some part of their product line.
In 2020 PCT brought on 10 new level 2 or 3 sub registrants. This is only in 7 months. The last one was yesterday. As these distributors develop their businesses they will add to revs. Doesn't happen over night unless your like Germinator who already has 17 franchises.
In 2019 seriously clean/ clean republic and nixall all became EPA subs. These companies with the companies they started in the AG, Human eye and wound use, disinfectants are already becoming a major force.
So many are stuck on the financials well this little company in litter river SC started selling Annihilyzer systems to health care facilities in 11/2018. Slowly they have been building the business. Not one hospital has ever returned a system. They announced a steady supply of hospital installations since bringing the Annihilyzer to market less then 2 years ago. Revs were up over 500% from 2018 to 2019 probably from the Annihilyzer sales and those large capacity machines.
All of a sudden CV-19 becomes a pandemic. PCT's business model was not of retail sales but selling Annihilyzer systems and large capacity machines gets slammed with orders for disinfectant. Infrastructure gets slammed also. As Gary said they shifted gears to the profit center of retail. Staff are doing multiple jobs and Gary hires more staff. The company is hiring more staff for the increase in demand. Takes time to hire and train.
Meanwhile demand is increasing for distributors and sub registrants. like I said 10 in just the 7 months of 2020.
Oh but I want my 2019 10k and 202o Q1 10Q.. No I don't want it I demand it. Something has to be wrong. Gary already said the issue is with the pandemic. Naaaa can't still be that the pandemic is getting better. Umm wrong it's getting worse in many states.
Look at what's happening the company is growing even as the fins are late. Oh, but maybe Gary doesn't give a damn about fins. Maybe Gary can get financing with a SS. Maybe he can get big investors to come in with a SS. lol Wrong if you don't think he wants the SS down as quickly as possible think again. The company is on the verge of being a dominant player in the HOCL industry if they aren't already.
So many with their eyes closed oh well. I've been adding and will continue to do so.
Good luck to everyone hope ya'll make the right decision when it comes to PCTL
PCTL level 2 and 3 distributors/ fluid manufactures with EPA Registrations by year registered
Year Registered 2014 PCT LTD. EXCELYTE VET Hydrolyte vetrinox 92108-1 registered 2/6/2014
Year registered 2018 DANOLYTE DANOLYTE GLOBAL, INC. 92108-1-91582 Registered 2/13/2018 Bio Blasting BIOBLAST DISINFECTANT 92108-1-91707 Registered 9/12/2018 Bio Blasting BIOBLAST DISINFECTANT KYUNG NONG CORPORATION S. Korea 92108-1-91707 Registered 9/12/2018
Anybody worried about PCTL ability to deliver their flagship product, "the Annihilyzer" just needs to look at the Family Corporate facilities of the Tippmann Group that will be producing them for PCTL! Check out the warehouse locations here:
Tippmann Affiliated Group is a family owned organization with a diversified group of business segments throughout North America and around the world. Current business segments include:
Manufacturing Sales and Marketing Warehousing Logistics Digital Media E-Commerce Approaching a half-century in business, Tippmann Affiliated Group businesses hold 17 patents and numerous product and service awards in various industries, including Automotive, Food Service, Refrigeration, Medical Device and Transportation.
My list of companies using PCTL fluids. If I missed any let me know. The list grows all the time. If you think PCTL isn't making money think again. If you think PCTL is a scam think again and check the websites. If you think a late financial is going to change the list below think again.
PCTL Distributors that have large capacity machines.
======================================================== falon Member Profile falon Wednesday, June 17, 2020 5:31:53 PM Re: None Post # of 114170 HOCI the gift that keeps giving.
Hypochlorous Acid was the catalyst that gave PCTL a financial boost that relieved the company of the burden of a continuous debt load. It also enabled them to prepare for a build out of their flagship product, the Annihilyzer/Large Volume Hydrolyte System for orders they received due to Covid-19 and eventually the UK and beyond.
So just what are the installation numbers of PCTL’s Annihilyzer/Large Volume Hydrolyte Systems?
I really don’t know however below is what I do know:
Oh Yea
FACTS not fiction
At least 36 Hospitals/Distributors using The PCTL Annihilyzer/Large Volume Hydrolyte Systems!
Hospitals (25)
Johnston UNC Health Care Hospital
Carson Tahoe Regional Medical Center
New York-Presbyterian?
NewYork-Presbyterian Morgan Stanley Children's Hospital
NewYork-Presbyterian / Weill Cornell Medical Center
NewYork-Presbyterian Lower Manhattan Hospital (NewYork-Presbyterian has another 5 hospitals in its network)
Yale New Haven Medical Center
UMass Medical Center
Coler/Goldwater Hospital
Metropolitan Hospital
Mount Sinai South Nassau Medical Center
Bellevue Hospital
NYU Langhorne
Lincoln hospital
Westchester County Medical Center
Harlem Hospital
Wyckoff Hospital
SUNY Downstate Medical Center
Coney Island Hospital
Kings county Medical Center
Queens Hospital
Methodist Hospital
Jacobi Medical Center
UK North Tees and Hartlepool NHS Foundation Trust
UK ?
Level 3 Distributors or Large Volume Hydrolyte System users (11):
4 systems to a Food Processing Customer
1 System Pure and Clean
1 System to Puerto Rico
1+ System to Ace Janitorial
2 Systems H2S Safe Treat Inc of Ada, OK
2 Systems BioBlasting LLC of Egg Harbor Township, New Jersey
1 System BOX Bioscience of Mount Pleasant, SC
1 System Colorado Springs, CO
I believe there are other Level 3 distributors, however I have not quite put the information together to confirm it. Pod cast interview https://stockdaymedia.com/?s=Pctl =================================== Re: None 0
Post # of 107661
More Cannabis DD.. PCTL distributors are killing it
The other day was posted a Cannabis connection to Growash. Continuing PCT Ltd. Research using the PCTL’s sub registrant number 92108-1-88098 Clean Republic there is another Cannabis connection. Clean Republic, Plantaid and Cause + Medic are associated with each other.
PlantAid has 2 products one designed to clean plants. (Due to EPA regulations they can’t say it does anything else in accordance with PCTL’s EPA reg number). The other product is used for equipment, tools and irrigation systems. Irrigation systems would be associated with hydroponic cultivation which is used in Cannabis growing besides fruits and veggies. You’ll also notice under “shop” they produce Hemp seeds. Again under “shop” you’ll see the connection back to Clean Republic.
============================================= beer $money Sunday, May 10, 2020 5:16:39 PM Re: beer $money post# 100472 Post # of 102445 Easy to make a sprayer! Tulsa Firefighters Use Hypochlorous Acid to clean their trucks.
My understanding these Firefighters are working with Advanced Environmental Solutions, Inc. ("AES, Inc.") of Meeker, Oklahoma.
Most recently, PCT Corp. has executed a collaborative agreement with Advanced Environmental Solutions, Inc. ("AES, Inc.") of Meeker, Oklahoma. AES, Inc. purchased two (2) high-volume units of PCT Corp.'s equipment and is building out a 2,500 s.f. production facility as it develops its oil & gas and Cannabis applications.
Re: None Post # of 102445 Only 3 trading days left before the 10-K.
PCT Ltd has...
* EPA Approved List N: Disinfectants for Use Against SARS-CoV-2 * EPA Approved List G: Antimicrobial Products Effective Against Norovirus * Green Seal Certified Equipment
May 8th, 2020 PCT LTD Continues Accelerated Expansion with NEW Hospital Installations and Fluid Distributors April 21st, 2020 PCT LTD Discusses Its Rapid Growth and Expansion Plans with The Stock Day Podcast April 16th, 2020 PCT Europe Ltd. Signs Distribution Agreement with UK NHS Company, Recieves Additional NYC Hospital Order April 15th, 2020 PCT LTD Reports Q3 2019 Financials; Revenue Increases 435%, Operating Expenses Decrease April 14th, 2020 PCT LTD Announces Receipts of New Purchase Orders for ANNIHILYZER Infection Control System in NYC Hospitals April 7th, 2020 PCT LTD Increases Fluid Capacity, Hires New Design Engineer, Ramps Up Midwest Fulfillment Capabilities March 27th, 2020 PCT LTD Obtains EPA Approval for Emerging Pathogens Labeling for use Against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19 March 25th, 2020 PCT LTD Expands Production Capacity and Accelerates Hypochlorous Acid Production and Sales March 18th, 2020 PCT LTD Receives Large Purchase Order for Recurring Sales of Fluids for Non-Medical Use and Explains Current Revenue Streams March 16th, 2020 PCT LTD Discusses Their Unique Annihilyzer™ Disinfecting System and Impact of The Coronavirus with The Stock Day Podcast March 13th, 2020 PCT LTD Adds International Distributor and Sells High-Volume Equipment to Existing Customer as a Result of Heightened Demand
Paradigm Convergence Technologies Corporation... The Right Company in the Right Place at the Right Time!
Don't get caught chasing it. =========================
Re: None Post # of 102018 New video from Alex G on LinkedIn
Medama HOCL being traditionally sprayed and electrostatically sprayed(via our Medama PCTL electrostatic cart)at a major Healthcare system in Westchester NY.
As the Director said to me, "hypochlorous, the new normal".
With the SDS HMIS ratings of O,O,O,O, this should definitely be the single choice/method for all institutions that are interested in disinfecting any surfaces; while ensuring that their customers understand, that their health and safety is their number one priority.
BIGBUCKS Member Level Friday, 05/01/20 12:27:58 PM Re: None 0 Post # 98897 of 98999 PCTL. EPA List N: Products with Emerging Viral Pathogens AND Human Coronavirus claims for use against SARS-CoV-2>the novel coronavirus that causes the disease COVID-19. EPA List N was last updated Today March 26, 2020 and added PCTL 92108-1 Hypochlorous acid Excelyte Vet How does EPA know that these products work on SARS-CoV-2? While these products have not been tested against SARS-CoV-2, the cause of COVID-19, they are expected to be effective based on: Demonstrated efficacy against a harder-to-kill virus; Qualified for the emerging viral pathogens claim; or Demonstrated efficacy against another human coronavirus similar to SARS-CoV-2. SARS-CoV-2 the novel coronavirus that causes the disease COVID-19 is a new virus. Such pathogens are often unavailable commercially for laboratory testing. https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2https://www.epa.gov/pesticide-registration/frequently-asked-questions-about-list-n-disinfectants-use-against-sars-cov-2#Q1 on[fq2D505A0D-3F24-4D0D-B592-02E1BCE41BBB.jpeg 1,125×1,033 pixels ======================= Chapmax Re: lucky,mydog post# 98713 0 Post # 98907of 98994
ACTION NEEDED Pctl has been trying to get in contact with the government to make them aware of our machine & what it can do We can help with & in our numbers send them copies of the DD that’s been posted
This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)
Info they’ll need: PODCAST LINK click Click in search....Pctl
This is who we can contact in government to make them aware of our machine.
point of entry for the submission of market research packages and meeting requests from interested stakeholders. The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought. At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed. Ideal technologies and products would (but are not required to) be: * - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities * - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability * - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)
Would you like to meet with a federal agency regarding a product that you are developing for COVID-19? If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.
Paradigm Convergence Technologies Corporation Summarized Due Diligence Sheet for Investing [color=red]
ACTION NEEDEDPctl has been trying to get in contact with the government to make them aware of our machine & what it can do We can help with & in our numbers send them copies of the DD that’s been
This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)
This is who we can contact in government to make them aware of our machine.
point of entry for the submission of market research packages and meeting requests from interested stakeholders. The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought. At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed. Ideal technologies and products would (but are not required to) be: * - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities * - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability * - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)
Would you like to meet with a federal agency regarding a product that you are developing for COVID-19? If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.
Company Site: para-con.com Twitter: @PCTL2020 Investor Relations Chesapeake Group - Get on the email list for news info@chesapeakegp.com
About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.
Mission: Infectious Disease and Contamination Control
About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.
The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.
---FINANCIAL INFO---
Filings: LINK
Current info as of 3/9/20 Authorized- 1,000,000,000 Outstanding- 511,315,300 Restricted- 35,139,690
Standard Registrar and Transfer Company 440 East 400 South, Suite 200 Salt Lake City, UT 84111 Phone: 801-571-8844 or 801-596-2150 www.standardtransferco.com Amy Merrill Email: amy@standardregistrar.com
---CURRENT CLIENT LIST---
1: Morgan Stanley Presbyterian Children’s Hospital. (3959 Broadway At, W 165 St, New York NY 10032)
2: Mount Sinai South Nassau Hospital (1 Healthy Way, Oceanside NY 11572)
3: Carson Tahoe Regional Medical Center (1600 Medical Pkwy, Carson City NV 89703)
4: SUNY Downstate Medical Center (450 Clarkson Ave, Brooklyn NY 11203)
6: Memorial Sloan Kettering Cancer Center ??? Maybe (1275 York Avenue New York, NY 10065)
7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial) (University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH) (University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)
8: New York Presbyterian Columbia Hospital (Ranked Top 5 in the Nation) (622 W 168th St, New York NY 10032) ---VP recently endorsed in a LinkedIn post---
9: New York Hospital -- as per PR Release (labeled #1 below)
---PR & RELATED INFORMATION---
1. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK
2. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK
3. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)
4. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK
5. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK
6. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK
7. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK
8. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)
9. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR
10. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK
11. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK
12. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK
13. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK
14. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK
15. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK
16. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK
17. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK
18. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK
3rd Quarter 10Q In final review with auditors & SEC Attorneys Expected to be completed in up to 3 weeks (updated per IR email--- expected in the next week)
10K Expected to be filed by April 13th
Convertible Notes "very active negotiations" to come to a resolve by time of 10K filing (April 13th)
No material change is O/S in months
very actively negotiating financing with negligible, if any, dissolution No anticipation of R/S
---Growth of about 400% in 2019--- on target to grow exponentially in 2020
G&A down significantly company become more efficicent, losses narrowed significantly down around 75% from 2018
---Currently Doing---
PCT UK joint venture partner Trial ongoing: Universities as well as hospitals involved to verify U.S. results "unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"
"Preliminary discussions between PCT UK and National Healthcare system of the UK"
---Markets--- Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities
Secondarily - Oil & Gas, remediation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)
Recently - Cannabis Industry - purveyor of service "Happy to discover our product greatly mitigates or totally eliminates the 3 major problems they are having"
---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20) 8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"
Endorsement from VP of MY Presbyterian [Suppressed Image]
Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:
Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).
In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a comprehensive portfolio of COVID-19 countermeasures. See below.
(For my privacy, I did redact my information on the image)
Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services
[Suppressed Image]
Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services
UPDATED DUE DILIGENCE 3-17 - RESEARCH NOW Below is a good portion of the DD done here, by myself and others. Do YOURS now! (Also pinned on top of board)
Paradigm Convergence Technologies Corporation Summarized Due Diligence Sheet for Investing
---GENERAL INFORMATION---
Company Site: para-con.com Twitter: @PCTL2020 - (I urge you to follow them and review their posts) Investor Relations Chesapeake Group - Get on the email list for news info@chesapeakegp.com
About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.
Mission: Infectious Disease and Contamination Control
About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.
The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.
---FINANCIAL INFO---
Filings: LINK
Current info as of 3/9/20 Authorized- 1,000,000,000 Outstanding- 511,315,300 Restricted- 35,139,690
Standard Registrar and Transfer Company 440 East 400 South, Suite 200 Salt Lake City, UT 84111 Phone: 801-571-8844 or 801-596-2150 www.standardtransferco.com Amy Merrill Email: amy@standardregistrar.com
---CURRENT CLIENT LIST---
1: Morgan Stanley Presbyterian Children’s Hospital. (3959 Broadway At, W 165 St, New York NY 10032)
2: Mount Sinai South Nassau Hospital (1 Healthy Way, Oceanside NY 11572)
3: Carson Tahoe Regional Medical Center (1600 Medical Pkwy, Carson City NV 89703)
4: SUNY Downstate Medical Center (450 Clarkson Ave, Brooklyn NY 11203)
6: Memorial Sloan Kettering Cancer Center ??? Maybe (1275 York Avenue New York, NY 10065)
7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial) (University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH) (University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)
8: New York Presbyterian Columbia Hospital (Ranked Top 5 in the Nation) (622 W 168th St, New York NY 10032) ---VP recently endorsed in a LinkedIn post---
9: New York Hospital -- as per PR Release (labeled #1 below)
---PR & RELATED INFORMATION---
1. 03/18/20 - PCT LTD Receives Large Purchase Order for Recurring Sales of Fluids for Non-Medical Use and Explains Current Revenue Streams PR LINK
2. 03/16/20 - PCT LTD Interview with Stock Day Podcast (MUST LISTEN) PR LINK
3. 03/13/20 - PCT LTD Adds International Distributor and Sells High-Volume Equipment to Existing Customer as a Result of Heightened Demand PR LINK
4. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK
5. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK
6. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)
7. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK
8. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK
9. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK
10. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK
11. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)
12. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR
13. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK
14. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK
15. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK
16. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK
17. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK
18. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK
19. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK
20. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK
21. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK
3rd Quarter 10Q In final review with auditors & SEC Attorneys Expected to be completed in up to 3 weeks (updated per IR email--- expected in the next week)
10K Expected to be filed by April 13th
Convertible Notes "very active negotiations" to come to a resolve by time of 10K filing (April 13th)
No material change is O/S in months
very actively negotiating financing with negligible, if any, dissolution No anticipation of R/S
---Growth of about 400% in 2019--- on target to grow exponentially in 2020
G&A down significantly company become more efficicent, losses narrowed significantly down around 75% from 2018
---Currently Doing---
PCT UK joint venture partner Trial ongoing: Universities as well as hospitals involved to verify U.S. results "unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"
"Preliminary discussions between PCT UK and National Healthcare system of the UK"
---Markets--- Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities
Secondarily - Oil & Gas, remidiation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)
Recently - Cannabis Industry - purveyor of service "Happy to discover our product greatly mitigates or totally elimiants the 3 major problems they are having"
---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20) 8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"
Endorsement from VP of MY Presbyterian and other execs [Suppressed Image]
[Suppressed Image]
[Suppressed Image]
[Suppressed Image]
Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:
Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).
In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a. comprehensive portfolio of COVID-19 countermeasures. See below.
(For my privacy, I did redact my information on the image)
Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services
================= exactly what the EPA said
Quote:
List N includes products that meet EPA’s criteria for use against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19.
The key word here is against The EPA does not come out and say any products on these lists will kill CV-19. However I doubt the EPA would use a strong word as against in the above statement.
Quote:
Note: Inclusion on this list does not constitute an endorsement by EPA. There may be additional disinfectants that meet the criteria for use against SARS-CoV-2. EPA will update this list with additional products as needed.
It's pretty obvious this disclaimer is stating the EPA does not endorse as in recommend any product that's listed. They do not because it would constitute marketing for that product.... The EPA also recognizes that there are other products that meet the criteria against SARS-CV-2 AKA Coronavirus. Why do they make this statement? Because there are other products that are registered with the EPA that are not on this list that meets the criteria against CV-19
Nothing hard to understand there. Here is the a pic of it below:
[Suppressed Image]
Lets move on
List N: Disinfectants for Use Against SARS-CoV-2 | Pesticide ...www.epa.gov › pesticide-registration › list-n-disinfectants-use-against-... If a product qualified for the Emerging Viral Pathogen Claim, it demonstrated efficacy against a harder-to-kill virus than the enveloped human coronavirus
From this statement we know that EXCELYTE which meets this criteria. How do we know this? We know because they are on the N list under EPA registration 92108-1. I also believe this Reg number can be used against the harder to lill Norovirus. Coronavirus is easier to kill than Norovirus. Any amount of basic DD will show that.
Below is the reg and product number for EXCELYTE [Suppressed Image]
Finally Below is the EPA reg link for EXCELYTE showing it's registered to PCT Ltd. This link is the original registration.
Pretty basic stuff is you ask me lol ============== Pics of the product - Sorry about it being sideways
[Suppressed Image]
[Suppressed Image]
[Suppressed Image]
============ PCT LTD Obtains EPA Approval for Emerging Pathogens Labeling for Use Against SARS-CoV-2, the Novel Coronavirus That Causes the Disease COVID-19 Business WireMarch 27, 2020, 9:49 AM CST
PCT LTD (OTC Pink: PCTL) ("PCTL") is pleased to announce that it has received approval for "emerging pathogens" labeling with the US EPA.
The application was filed under the guidance document "Guidance to Registrants: Process for Making Claims Against Emerging Viral Pathogens Not on EPA-Registered Disinfectant Labels." It was approved on March 26th, 2020. The guidance document provides the following information regarding different classes of viruses and their resistance to being killed by disinfectants:
EPA and the Centers for Disease Control and Prevention (CDC) recognize that certain microorganisms can be ranked with respect to their tolerance to chemical disinfectants. The Spaulding Classification model, used by CDC, tiers microorganisms in accordance with the level of resistance to being killed (inactivation) by typical disinfectant products. With this approach viruses are divided into three viral subgroups (small non-enveloped, large non-enveloped, and enveloped) based on their relative resistance to inactivation … According to this hierarchy, if an antimicrobial product can kill a small, non-enveloped virus it should be able to kill any large, non-enveloped virus or any enveloped virus. Similarly, a product that can kill a large, non-enveloped virus should be able to kill any enveloped virus.
Small, Non-Enveloped Viruses (<50 nm): These small, non-enveloped viruses can be highly resistant to inactivation by disinfection. Despite the lack of a lipid envelope, these organisms have a very resistant protein capsid…
Large, Non-Enveloped Viruses: Compared to small, non-enveloped viruses, these viruses are less resistant to inactivation by disinfection. Although they have a resistant protein capsid, their larger size (50-100nm) makes them more vulnerable than their smaller viral counterparts…
Enveloped Viruses: Enveloped viruses are the least resistant to inactivation by disinfection. The structure of these viruses includes a lipid envelope, which is easily compromised by most disinfectants. Once the lipid envelope is damaged, the integrity of the virus is compromised, thereby neutralizing its infectivity.
In addition to being "an EPA-registered, hospital/healthcare or broad-spectrum disinfectant …", in order to meet product eligibility criteria, the product "should have disinfectant efficacy claims against at least one of the following viral pathogen groupings:
a) A product should be approved by EPA to inactivate at least one large or one small non-enveloped virus to be eligible for use against an enveloped emerging viral pathogen.
b) A product should be approved by EPA to inactivate at least one small, non-enveloped virus to be eligible for use against a large, non-enveloped emerging viral pathogen.
c) A product should be approved by EPA to inactivate at least two small, non-enveloped viruses with each from a different viral family to be eligible for use against a small, non-enveloped emerging viral pathogen.
This approach, where disinfectant products registered for use against viral pathogens in one category of the Spaulding Classification model can be presumed effective against viral pathogens in less-resistant categories, is intended to serve as a conservative approach to identifying disinfectant products likely to be effective against emerging pathogens."
As a result of meeting all of the Product Eligibility Criteria, PCT LTD can now make the following statement "only through the following communication outlets: … "1-800" consumer information services, social media sites and company websites (non-label related) … [as well as] technical literature distributed exclusively to health care facilities, physicians, nurses and public health officials":
This Product meets the criteria to make claims against certain emerging viral pathogens from the following viral category[ies]:
Enveloped Viruses
Large Non-Enveloped Viruses
Small Non-Enveloped Viruses
For an emerging viral pathogen that is a/an… …follow the directions for use for the following organisms on the label: Enveloped virus Norovirus Large, non-enveloped virus Norovirus Small, non-enveloped virus Norovirus, Rhinovirus (Type 16)
Hydrolyte® has demonstrated effectiveness against viruses similar to SARS-CoV-2 virus on hard, non-porous surfaces. Therefore, Hydrolyte® can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/community/home/cleaning-disinfection.html for additional information.
COVID-19 is caused by SARS-CoV-2 virus. Hydrolyte® kills similar viruses and therefore can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/community/home/cleaning-disinfection.html for additional information.
"We are very pleased to receive approval for an "emerging pathogens" claim on our product label," says CEO Gary Grieco. "It represents an important step for us as a business and in helping to control the spread of infectious disease as a whole. Additionally, we are now prequalified for future emerging pathogens of any virus classification."
Due to the ongoing coronavirus pandemic, PCT LTD has seen an increased number of inquiries from existing clients, sub-registrants, and distributors; in addition to new and prospective customers. The company recently announced that they had temporarily shifted their focus towards producing mass quantities of disinfecting fluids to meet growing demand.
"Fluid sales have been tremendous for us," says PCT Ltd CEO Gary Grieco. "To put it simply, we are routinely shipping fluids out at rapid pace and into the hands of trained professionals where our product can be put to good use fighting the spread of infectious disease in our communities. We are limited only by our capacity to produce the fluids, but we expect to double our production capacity by April 1st."
Additional News and Corporate Updates:
PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL.
About PCT LTD:
PCT LTD ("PCTL") focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting, cleaning and tracking technologies. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, "PCTL" aspires to and is actively engaged in preparations for up-listing its common stock to a national securities exchange. The Company established entry into its target markets with commercially viable products in the United States and now continues to gain market share in the U.S. and U.K.
Forward-Looking Statements:
This press release contains "forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."
Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: the impact of having met the EPA Criteria for use Against SARS-CoV-2, actual sales derived by the Company; the transition to producing large quantities of fluids; PCTL's and its subsidiary's business prospects; PCTL's ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCTL to execute its business plan; any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements PCTL makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the SEC. PCTL undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Gary Grieco, CEO and Chairman, PCT LTD (843) 390-7900 Office (843) 390-2347 Fax www.para-con.com www.pctcorphealth.com www.survivalyte.com
Brokers and Analysts: Chesapeake Group +1-410-825-3930 info@chesapeakegp.com ==================================================================================================================. CANADA INFO & LINKS BokehRebl Tuesday, 03/31/20 10:29:25 PM Re: Long term post# 78282 ? 0 Post # 78283 of 78339
Here’s THE list I put together of all relevant contact in the US and Canadien Government, Feel free to add more!
Louisiana Alexander Billioux, MD, DPhil [Bio] Assistant Secretary of Health Alexander.Billioux@LA.GOV
Maine Nirav Shah, MD, JD* Director, Maine Center for Disease Control and Prevention Nirav.Shah@Maine.Gov
Maryland Robert Neall Secretary of Health Frances B. Phillips, RN, MHA [Bio] Deputy Secretary for Public Health Services S/THO Designee robert.neall@maryland.gov
Michigan Joneigh Khaldun, MD, MPH, FACEP [Bio] Chief Deputy Director for Health and CME khaldunj@michigan.gov
Minnesota Jan Malcolm [Bio] Health Commissioner jan.malcolm@state.mn.us
Mississippi Thomas Dobbs, MD, MPH* State Health Officer thomas.dobbs@msdh.ms.gov
Missouri Randall W. Williams, MD, FACOG [Bio] Director randall.williams@health.mo.gov
Montana Sheila Hogan Director Gregory Holzman, MD [Bio] Chief Medical Officer S/THO Designee gHolzman@mt.gov
Nebraska Dannette Smith, MSW * Chief Executive Officer, Nebraska Department of Health & Human Services Gary Anthone, MD Chief Medical Officer and Director, Division of Public Health S/THO Designee Dannette.Smith@nebraska.gov
Nevada Lisa Sherych, MBA* Administrator lsherych@adsd.nv.gov
New Hampshire Lisa Morris, MSSW [Bio] Director, Division of Public Health Service lisa.morris@dhhs.nh.gov
New Jersey Judith Persichilli RN, BSN, MA* Commissioner of Health Judith.Pershichilli@doh.nj.gov
New York Howard Zucker, MD, JD [Bio] Commissioner of Health howard.zucker@health.ny.gov
North Carolina Mark Benton [Bio] Assistant Secretary for Public Health mark.benton@dhhs.nc.gov
North Dakota Mylynn K. Tufte, MBA, MSIM, RN [Bio] State Health Officer mylynntufte@nd.gov
Ohio Amy Acton, MD, MPH [Bio] Director of Health DirectorAmyActon@odh.ohio.gov
Oklahoma Gary Cox, JD* Commissioner of Health GaryC@health.ok.gov
Oregon Lillian M. Shirley, BSN, MPH, MPA [Bio] Public Health Director lillian.shirley@state.or.us
Pennsylvania Rachel Levine, MD [Bio] Secretary of Health ralevine@pa.gov
Puerto Rico Rafael Rodriguez Mercado, MD, FACS, FAANS Secretary of Health Catherine De La Cruz-Duran* S/THO Designee drrafael.rodriguez@salud.pr.gov
Rhode Island Nicole Alexander-Scott, MD, MPH [Bio] Director nicole.alexanderscott@health.ri.gov
South Carolina Richard Toomey, MHA, DHA [Bio] Director, South Carolina Department of Health and Environmental Control Rick.Toomey@dhec.sc.gov
South Dakota Kim Malsam-Rysdon [Bio] Secretary kim.malsam-rysdon@state.sd.us
Tennessee Lisa Piercey MD, MBA, FAAP [Bio] Commissioner tn.health@tn.gov
Texas John Hellerstedt, MD [Bio] Commissioner john.hellerstedt@dshs.texas.gov
Utah Joseph Miner, MD [Bio] Executive Director joeminer@utah.gov
Vermont Mark Levine, MD [Bio] Commissioner of Health mark.levine@vermont.gov
Virginia M. Norman Oliver, MD, MA [Bio] State Health Commissioner norm.oliver@vdh.virginia.gov
Washington John M. Wiesman, DrPH, MPH [Bio] Secretary of Health secretary@doh.wa.gov
West Virginia Cathy Slemp, MD, MPH [Bio] Commissioner and State Health Officer catherine.slemp@wv.gov
Wisconsin Jeanne Ayers, RN, MPH [Bio] Administrator, Division of Public Health Jeanne.Ayers@dhs.wisconsin.gov
Wyoming Alexia Harrist, MD, PhD [Bio] State Health Officer alexia.harrist1@wyo.gov —————————————
davidsan Wednesday, April 1, 2020 4:57:18 PM Re: None Post # 78774 of 78834 Can PCTL's fluid turn sour crude oil into sweet?
I vaguely remember this was something said in discussing why that large unnamed oil&gas company was so interested in setting up the customized trial they are doing. I remember clearly that it helped make the liquid involved in fracking much more environmentally friendly, much more green, with a more pure and less costly product, something to that effect. There was some big reason why that oil&gas company was so excited about it. If the oil&gas industry incorporates this into their standard processes, with the sheer volume of this fluid they will need every day, that will be HUGE, just that one piece of all this alone. Somewhere in there I thought I remembered that in the process it helped turn sour crude into sweet, just don't recall how specific that point was.
Anyone here remember?
This is so much more than just hospitals and spraying to kill the coronavirus. The agricultural/cannabis industry and oil&gas industry customized trials are going on as well.
And, of course, the UK trials are about to hit (The UK hospital trial already completed, and the 2 university studies are supposed to complete the end of March to first week of April, meaning anytime now). Just waiting on results and orders, both expected to be very favorable.
Hypochlorous Acid Market Demand Would Increase Rapidly Hypochlorous Acid Market: Excellent Microbial and Oxidizing Properties Hypochlorous acid is a weak acid formed by dissolving chlorine in water. It possesses excellent microbial and oxidizing properties. It is used as a disinfectant agent in medical, water treatment, and food additives in food & beverages industry. Sodium hypochlorite and calcium hypochlorite are the two types of hypochlorous acid. Sodium hypochlorite is a widely consumed hypochlorous acid. Sodium hypochlorite can be easily stored and transported. It is more effective than chlorine gas in various applications. Read report Overview@ https://www.transparencymarketresearch.com/hypochlorous-acid-market.html Hypochlorous acid is employed in various end-user industries such as water treatment, wound management, food & beverages, oil & gas, and personal care. Demand for hypochlorous acid in the wound management segment is projected to rise significantly in the near future. Hypochlorous acid acts as an excellent disinfectant in wound healing applications. It accelerates the healing process of any wound and other infections such as eye infection, ear infection, etc. Hypochlorous acid has excellent disinfectant properties, which help destroy pathogens, bacteria, and fungi. Request PDF Brochure@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=68783 Key drivers of Hypochlorous Acid market Rise in demand for oxidizing and disinfecting agents in order to provide quality water is driving the global hypochlorous acid market. Hypochlorous acid is highly cost effective. It is non-toxic to humans and animals. Therefore, it is highly preferred in the water treatment industry. Rise in usage of hypochlorous acid in sterilizing bacterial infection by drying out blood cells is boosting its demand in the medical industry. Hypochlorous acid is also used as an active sanitizing agent in swimming pools and skin cleansing agent in cosmetic applications. It is used in the manufacture of calcium hypochlorite (Ca(OCl)2) and sodium hypochlorite (NaOCl), which are further used in the manufacture of disinfectants, bleaches, and deodorants. Food & Beverage Industry and Wound Management to offer attractive opportunities Increase in usage of hypochlorous acid in the food & beverages industry is estimated to provide lucrative opportunities to manufacturers of hypochlorous acid in the near future. Hypochlorous acid is used for cleaning food processing equipment and dish washers. It is also employed as food additive in processing poultry products and seafood products. Hypochlorous acid is gaining momentum as a potential wound care agent in the pharmaceutical industry. It is a highly effective wound irrigation solution, which is entirely safe for human tissues. It aids in elimination of unpleasant wound odor and removes bacteria from wound surface. Hypochlorous Acid may form Explosive Gas in Concentrated Form likely to Restrain Market Hypochlorous acid is highly dangerous and can form explosive gas if used in concentrated form. This is anticipated to restrain the market during the forecast period. When exposed to air, it disintegrates and causes nausea, abdomen pain, etc. If released in water bodies, hypochlorous acid may harm aquatic animals, thereby adversely affecting biodiversity. These factors are estimated to restrain the demand for hypochlorous acid during the forecast period. Stuck in a neck-to-neck competition with other brands? Request a custom report on competition on Hypochlorous Acid Market here Asia Pacific Expected to Hold Leading Share in the Global Hypochlorous Acid Market In terms of region, the demand for hypochlorous acid can be split across five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of consumption, Asia Pacific dominated the global hypochlorous acid market in 2018. Developing economies such as China, India, Vietnam, and Indonesia are the leading consumers of hypochlorous acid in Asia Pacific. Rapid industrialization and increase in demand for sodium hypochlorite in chemical, agriculture, and pharmaceutical industries are anticipated to fuel the hypochlorous acid market during the forecast period. Demand for hypochlorous acid in countries in Europe such as Germany, France, and the U.K. is projected to increase during the forecast period primarily due to the rise in demand for sodium and calcium hypochlorite in the food & beverages industry in the region. The U.S. is the leading consumer of hypochlorous acid in North America. Increase in demand for hypochlorous acid in industrial applications such as cooling water treatment is propelling the market in the U.S. Latin America and Middle East & Africa are highly dependent on hypochlorous acid import. This is likely to hamper the sales of hypochlorous acid in these regions. However, production capacity expansion by various manufacturers in Brazil, Mexico, and GCC is expected to augment the demand for hypochlorous acid in Latin America and Middle East & Africa during the forecast period. Key Players in Hypochlorous Acid Market: New product launches and mergers & acquisitions are the key strategies adopted by top players operating in the market. For instance, in 2018, URGO Medical, a leading player in wound care products, entered into an asset purchasing agreement with REALM Therapeutics, a biopharmaceutical company based in the U.S. REALM Therapeutics engages in research activities to discover new hypochlorous acid based treatments for atopic dermatitis and allergic conjunctivitis. This acquisition is expected to help URGO Medical become the leading player in advanced wound care business across the globe. Key players operating in the global hypochlorous acid market include Lenntech B.V. BASF SE Arkema S.A. Lonza. Inovyn Chlorvinyls Limited Olin Corporation Nouryon (Previously under Akzo Nobel N.V.'s coating division) Occidental Petroleum Corporation Kuehne Company AGC Chemicals Surpass Chemical Company, Inc. Westlake Chemical Corporation Clorox Company Tianjin Ruifuxin Chemical Tosoh Corporation Aditya Birla Chemicals Aqualution Systems Ltd Ultrapure HOCL (Pty) Ltd Others
=================== Friday, April 3, 2020 10:10:28 AM Cherry Re: None Post # 80097 of 80187 WHY YOU WANT TO BUY ALL THE PCTL YOU CAN
Right now, IMO, before PCT LTD (ticker PCTL) announces the UK hospital results which might potentially lead to 600+ hospital installations in the UK, before the March 2020 revenues from increased fluid sales are known, before the scientific data on treating disease/mold/fungi in the citrus & cannabis industries is announced, before results from the oil & gas industry testing, and before the delayed 2019 Q3 of which will contain outdated information from over 6 months ago-
People reading here may have read and seen, in bits and pieces, all these things below.
How anyone interprets & verifies anything, and researches further, is up to them. Nothing here is advice.
Since late 2019: More hospitals, More distribution, More geographic regions, More production capacity, More sales of the fluid itself & increasing dramatically, EPA approved on List N to disinfect surfaces for NCOV-19-SARS-2, Existing clients are buying more systems or extending their contracts,
=============== Tuesday, 04/07/20 11:13:24 AM Re: Patience 1 post# 81708 0.005 Post # 81730 of 82300
Quote:
NEWS OUT!! 4/7/20, 9:55 AM LITTLE RIVER, S.C.--(BUSINESS WIRE)
PCT LTD (OTC Pink: PCTL) ("PCTL") is excited to announce they have increased production capacity at their Little River, South Carolina facility.
Updating an earlier release (March 25th), the South Carolina facility is now capable of producing up to 10,000 gallons of fluids per day. A marked increase over earlier capabilities. The company is now better positioned to meet the growing demand for its Hypochlorous Acid-based disinfecting fluids.
“Our team has been working around the clock over the last several weeks to make this happen,” says Stuart Emmons, PCTL Executive VP of Engineering and R & D. “The South Carolina facility is now better positioned to fulfill the daily orders we have been receiving.”
Due in part to the ongoing coronavirus pandemic, the company has seen an exponential increase in sales and inquiries from current and prospective customers. Late last month the company shifted its short-term focus towards fluid production and sales to meet increasing demand.
“It’s supply and demand,” according to PCTL CEO Gary Grieco. “The demand is there and now so is the supply. We needed to shift our focus towards where we can have the most impact and do the most good for our customers and the communities they serve. At the same time, this presents an opportunity for us to elevate our profile, grow our business, and showcase how effective our products can be in the ongoing fight against the spread of infectious disease.”
The company has also been hiring additional support staff to support growing business operations. Most recently, the company engaged Joseph Tippmann, graduate of The University of Michigan’s Industrial Design and Architecture program, as a new design engineer. Tippmann joined the company on a contract basis initially and has spent the past two weeks performing design updates on Annihilyzer and Hydrolyte Rack systems in addition to helping design a more modular system for easier assembly.
Tippmann is also a co-owner of Werks Manufacturing, a Fort Wayne, Indiana based manufacturing company which PCTL engages for the purpose of manufacturing and assembling parts for use in the company’s Annihilyzer® Infection Control System and other systems.
Werks Manufacturing is expanding their operation and will increase parts and assembly production to meet PCTL’s growing demand. In addition, Werks will also serve as a fluid depot for PCTL’s clients in the northern Midwest part of the United States. Werks will initially be capable of producing up to 4,000 gallons per day of disinfecting fluids, including Hydrolyte®, for sale and use by PCTL to clients in Detroit, Chicago, and throughout the region. This fluid production capacity can be increased as needed to serve growing demand.
“We are continuing our rapid growth plans,” says Grieco. “Through strategic partnerships, distribution agreements, and more, we are gaining market share, increasing revenue at a rapid pace, and growing our business both quickly and efficiently.”
Additional News and Corporate Updates:
PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL. ====================
Wednesday, April 8, 2020 1:22:30 PM Beer money Re: None Post # 82319 of 82350 Yes Gary Grieco, PCTL CEO, stated, "As a result of the capabilities and benefits of our products, many companies and municipalities across a variety of industries and geographic locations are engaging in intense discussions with PCT LTD."
PCTL "The 800 pound gorilla, Corona-virus, that has opened up a huge opportunity for us and I can not say any more than that we have been contacted by, and are actively negotiating to address the problem with both companies and government officials and I can not say more than that."
In addition, Grieco further commented, "All of our hospital customers using our infection control system and disinfectant are utilizing the systems as a front-line defense throughout their facilities, including in all public area such as restrooms, lobbies, waiting rooms, elevators, corridors, cafeterias, etc. all throughout the day and night and in the presence of patients, staff and visitors."
============ Thursday, April 9, 2020 10:01:52 AM Re: None Post # 82599 of 82789 Hypochlorous Acid Okay For Easter Eggs Hypochlorous acid is cleared by the FDA for use on meat, poultry, fish & seafood, fruits & vegetables and shell eggs as a no-rinse sanitizer. FCN 1811 is a Food Contact Notification (FCN) from the FDA for using electrolytically generated hypochlorous acid as an antimicrobial agent in an aqueous solution in the production and preparation of whole or cut meat and poultry; processed and preformed meat and poultry; fish and seafood; fruits and vegetables; and shell eggs. To read more about food contact notification 1811, visit the FDA website in the link below. https://www.hypochlorousacid.com/regulation [Suppressed Image]
================== Thursday, April 9, 2020 10:35:37 AM Re: None Post # 82670 of 82807 Why the NHS and Private Clinics Should Look Further than Alcohol-Based Sanitisers The CoViD-19 pandemic has brought alcohol to the fore; whether it is the amount the British public is consuming to get through self-isolation or the level required in hand sanitiser to make it effective, the news stories are everywhere. Many of these revolving around the shortage of traditional alcohol-based hand sanitisers and how prices are soaring. With this being the case, why then don’t the NHS and other health care facilities look elsewhere? Is there no other option? In fact, there is another option which is rapidly emerging as the new go-to sanitiser during the CoViD-19 pandemic; Hypochlorous Acid (HOCl). What is Hypochlorous Acid? HOCI is generated when white blood cells attack harmful bacteria and is harmless to the human body. In December 2019 Optometry Times published an article on HOCl and they explain it much better than I can… “HOCl is a weak acid that occurs naturally in our body. Neutrophils are white blood cells that are the first to arrive on site when an invading pathogen is detected. Neutrophils will chase down and engulf the pathogen through phagocytosis. Upon contact, neutrophils release a burst of bactericidal chemicals including its most powerful oxidizing agent, HOCl. This kills the pathogen by tearing down the cell membranes and proteins”. Optometry Times called HOCl “the perfect weapon to fight germs. It hits hard against pathogens like Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeroginosa. Yet this powerful weapon is 100 percent safe for humans, chemical free, non-toxic and all-natural”. Due to these attributes HOCl is being widely used in South Korea in their battle against CoViD-19, disinfecting everything from food to people to hospital wards and their mass transit systems. Looking at the way in which they have taken control of the spread of the virus it is clear to see that HOCl can also help the United Kingdom to gain the upper hand in this struggle. https://www.belle.org.uk/news-1/2020/4/2/why-the-nhs-and-private-clinics-should-look-to-hypochlorous-acid-rather-than-alcohol-based-sanitisers
=============
beer $money ?
Sunday, April 12, 2020 8:04:27 PM Re: BIGBUCKS post# 83703
Post # 83709 of 83745 Alex Guttman Author> Huge interest being developed on LinkedIN VP marketing and Research at Ace Janitorial, Sales Mgr Escalator Cleaning company, Senior VP HAI Consultants
Randy Stiles can't mention names without permission but I can say that most of the major healthcare systems in NYC are now using our system
Randy Stiles +Executive Account Manager at Paylidify
Jon Pickett, MBA is this being used at all Memorial Healthcare Locations? The feedback on the system has been great.
Jody Read CEO at PCT Health, PCT LTD
Glad to see that the efforts of the entire team at ACE and PCT to bring this system to market has been a success and we are looking forward to placing these systems into every hospital, surgical center, nursing homes, and long-term care facilities!
Good am Mr Jody.could I represent your company in Dubai.? Tnx
Fritz Oehler Executive Director at Sprenger Health Care Systems Looks like this product could be an answer to many infection control issues in our industry.
Sunday, April 12, 2020 8:53:14 PM Re: BIGBUCKS post# 83629
Post # 83715 of 83745 Some additional DD. The full section in that recent PCTL release includes: Quote:
The company has also been hiring additional support staff to support growing business operations. Most recently, the company engaged Joseph Tippmann, graduate of The University of Michigan’s Industrial Design and Architecture program, as a new design engineer. Tippmann joined the company on a contract basis initially and has spent the past two weeks performing design updates on Annihilyzer and Hydrolyte Rack systems in addition to helping design a more modular system for easier assembly. Tippmann is also a co-owner of Werks Manufacturing, a Fort Wayne, Indiana based manufacturing company which PCTL engages for the purpose of manufacturing and assembling parts for use in the company’s Annihilyzer® Infection Control System and other systems. Werks Manufacturing is expanding their operation and will increase parts and assembly production to meet PCTL’s growing demand. In addition, Werks will also serve as a fluid depot for PCTL’s clients in the northern Midwest part of the United States. Werks will initially be capable of producing up to 4,000 gallons per day of disinfecting fluids, including Hydrolyte®, for sale and use by PCTL to clients in Detroit, Chicago, and throughout the region. This fluid production capacity can be increased as needed to serve growing demand.
I could not find much on google in regards to Joseph Tippmann. I did find Werks Manufacturing Inc. = http://werksmfg.com ;... but ... website is “under construction”. It appears to be located at 2300 Meyer Road Fort Wayne, IN 46803. It appears the phone number might be (260) 428-2698. Also at this address appears to be: Advanced Media Integration LLC = Video production service = Vincent P Tippmann. same phone number?
I did also find Vincent P. Tippmann at this website: https://vptag.com/ Tippmann Affiliated Group is a family owned organization with a diversified group of business segments throughout North America and around the world. Approaching a half-century in business, Tippmann Affiliated Group businesses hold 17 patents and numerous product and service awards in various industries, including Automotive, Food Service, Refrigeration, Medical Device and Transportation. As it stands today, Tippmann Affiliated Group remains a family owned organization with a diversified group of business segments throughout North America and around the world. Headquartered in Fort Wayne, IN, Tippmann Affiliated Group operates its main campus on 75 acres and 810,000 sq/ft. of manufacturing and office space. 4410 New Haven Ave Fort Wayne, IN 46803. Phone:(260) 428-2500. It appears that 2300 Meyer Road Fort Wayne, IN 46803 is immediately adjacent to 4410 New Haven Ave Fort Wayne, IN 46803. Father & son? Could Vincent Tippman be the co-owner of Werks Manufacturing (together with Joseph Tippmann?
=====================
Ronin Wednesday, 04/15/20 10:42:51 AM Re: TKane post# 86153 Post # 86171 of 86190
News hit DOW JONES and BUSINESS wire! Lots of eyes on this now!
Evaluate Wednesday, April 15, 2020 3:12:04 PM Re: Evaluate post# 86473 Post # 86479 of 86491 https://pureandclean.us/disinfectant-sanitizer-gallon/ It appears that Pure & Clean is a distributor for PCT's HOCl, at 460 PPM, since their web page shows it is a distributor of EPA Reg. No. 92108-1. Only available in the following states: Florida, Kansas Maryland, Missouri, Nevada, Oklahoma and Texas. For all other states, please order the Surface Cleaner Pro products: https://pureandclean.us/surface-cleanser-pro/ Pure&Clean Disinfectant/Sanitizer? 460 ppm HOCl. This is a New Generation Disinfectant formulated using Hypochlorous Acid (HOCl) that cleans, deodorizes, and disinfects. As a distributor of EPA Reg. No. 92108-1, the product pure&clean™ (EPA Reg. No. 92108-1-88098) is included on the list of products approved by the US
=====================
BIGBUCKS Wednesday, April 15, 2020 3:09:42 PM Re: None Post # 86478 of 86491 PCT LTD Reports Q3 2019 Financials; Revenue Increases 435%, Operating Expenses Decrease
At 0’37: it shows that the “Annihilyzer is “Presented By: Annihilare and Paradigm Convergence Technology Corp” I was surprised to see this. Question: Does Annihilare also share in the revenues/profits of selling/leasing Annihilyzers?
=========== BRITT2575 ? Friday, 04/17/20 12:41:50 AM Re: None ? 0 Post # 88648 of 88658
PCT EUROPE LTD SIGNS DISTRIBUTION AGREEMENT WITH UK NHS COMPANY, RECEIVES ADDITIONAL NYC HOSPITAL ORDER April 17 2020 - 12:08AM InvestorsHub NewsWire Print PCT EUROPE LTD SIGNS DISTRIBUTION AGREEMENT WITH UK NHS COMPANY, RECEIVES ADDITIONAL NYC HOSPITAL ORDER
Little River, SC -- April 17, 2020 -- InvestorsHub NewsWire -- PCT LTD (OTC Pink: PCTL) is pleased to announce new growth and expansion activities in the UK and NYC. PCT Europe Ltd, the UK-based partner of PCTL is pleased to announce they have signed an exclusive trading partnership/distributor agreement with an NHS (U.K. National Health Service) company.
In tandem with PCT Europe Ltd, the UK NHS company will introduce PCT technology to each NHS Hospital Trust with the intention of them rolling out PCT's unique technology and system throughout the health services 233 Trusts comprising over 600 hospitals. In addition, approximately 14,000 Care Homes in the U.K. will also be introduced to PCT's technology. A steady flow of orders is expected to commence throughout the remainder of 2020 and into 2021.
The first PCT system has now been installed in a large NHS hospital in the north of England. This system is expected to enter clinical service early in May once the final series of biological tests of the PCT hospital disinfectant solution have been completed. Results of these tests have so far demonstrated that the PCT disinfectant has met or exceeded its ability to kill the range of pathogens previously achieved during EPA tests in the United States.
"We couldn't be happier with the results thus far in our UK trials and are delighted with the progress our UK partner is making. This arrangement will introduce our system to thousands of hospitals and healthcare facilities," says PCTL CEO Gary Grieco. "At the same time, the reality of the current healthcare crisis both domestically and abroad is sobering. We're thrilled to be able to grow our business but nevertheless remain focused on our core mission which from day one has always been helping people."
The company continues to expand domestically as well. Following an earlier release dated April 14th, the company is also announcing an additional purchase order for PCT Corp.'s Annihilyzer® Infection Control Systems in New York City.
The order comes from a large NYC hospital with a current bed count in excess of 2,500. Installation will be made in coordination with PCT Corp's primary healthcare distributor, ACE Janitorial Services.
"With three PO's for our infection control system this week and more on the way, we continue to make strides both in growing our business as well as our goal of helping our clients fight the spread of infectious diseases," says Grieco. "We are on pace for unprecedented and record growth in all areas of our business."
Additional News and Corporate Updates:
PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL.
Post # 92362 of 92385 PCTL> UK NHS is the largest single healthcare delivery organisation in the world.
SELLING TO THE NHS
SUMMARY This guide outlines the structures that exist to help companies contact and sell existing and innovative products into the NHS, a huge organisation which can appear very complex.
IN BRIEF NHS Supply Chain Procurement routes – national, regional and local contracts
Products for GP prescription
Estates – capital equipment
Innovation – new products
The NHS is the largest single healthcare delivery organisation in the world. It constitutes a major opportunity for UK medical device companies. NHS trusts can purchase products through one of five main routes:
Directly from suppliers using National Framework Contracts
From the NHS Supply Chain which provides end-to-end supply chain services incorporating procurement, logistics, e-commerce and customer and supplier support
The NHS Supply Chain is a single organisation created for the benefit of NHS trusts, hospitals and other healthcare organisations. The organisation combines the former NHS Logistics Authority, significant parts of the NHS Purchasing and Supply Agency, expertise in healthcare logistics from DHL and procurement experience from Novation.
PROCUREMENT ROUTES National contracts Tenders: Contracts for products and services valued at over £90,319 (01 Jan 2008) must be advertised in the Supplement to the daily Official Journal of the European Union (OJEU). Procurement levels change, but you can confirm the current level by visiting: http://www.ojec.com.
NHS-sid: This is the official NHS supplier information database on which companies can enter their information for free:
http://www.sid4health.nhs.uk. It rationalises the management of pre-qualification data during the procurement process and can only be fully accessed by authorised NHS personnel. Suppliers looking to compete for advertised NHS contracts must still submit applications in the required format. Any supplier is free to register its services on NHS-sid. The information published is made freely available to NHS users. Registering on this system does not imply that a supplier has any special or ‘approved’ status. Regional contracts Collaborative organisations: Most NHS trusts are now partners in ‘collaborative procurement organisations’ where, normally on a regional basis, they can share information and resources to achieve economies of scale.
Local contracts Individual trust contracts: Local contracts are often managed by a trust’s supplies department. Its approach to suppliers will vary according to the value, size and complexity of its requirements. DH has set down procurement guidelines indicating that for contracts valued below £3,000 a trust should ask for telephone quotes; for contracts valued between £3,000 and £10,000, it should request a minimum of three written quotes; for contracts valued above £10,000, a minimum of three formal written tenders should be sought. Actual interpretations of these guidelines vary from trust to trust.
PRODUCTS FOR GP PRESCRIPTION
Suppliers wishing to list their products under the Drug Tariff for prescription by GPs or nurses must seek approval from the NHS Business Service Authority (NHSBSA). These will usually be products for self-administration, possibly with a carer’s help, and will normally fall into the following categories: dressings, bandage and associated appliances, incontinence appliances, stoma appliances, and chemical reagents. If the NHSBSA grant approval, the cost, either comparatively with other similar products, or, if it is a new treatment regime, by comparison with alternatives, will be reimbursed. You can access the application form at: www.nhsbsa.nhs.uk.
ESTATES – CAPITAL EQUIPMENT
DH uses two major Public and Private Partnerships (PPPs) to deliver its NHS Plan: the Private Finance Initiative (PFI) and NHS Local Improvement Finance Trust (LIFT). The NHS ProCure 21 Framework brings the NHS and the construction industry together for new-build projects. You can find information on PPPs and associated procurement policies at: www.dh.gov.uk.
INNOVATION – NEW PRODUCTS
The procurement routes above apply to established products. If you are a supplier of innovative products, you should be aware of the organisations involved in product approval:
The UK Medicines and Healthcare product Regulatory Agency (MHRA) This is the government agency responsible for ensuring that medicines and medical devices work and are safe.
Regulatory affairs: Medical devices can only be placed on the market in the UK/EU if they are certified safe, are of the required quality to fulfill the manufacturer’s ‘intended purpose’ and comply with the appropriate Medical Device Directive (CE marking). The MHRA audits the performance of manufacturers and notifies bodies responsible for granting CE marks. You can find more details at: www.mhra.gov.uk.
Clinical trials: The MHRA approves clinical trials/investigations and provides guidance for manufacturers. To obtain a CE mark, a manufacturer must show that the device complies with the relevant ‘Essential Requirements’ of the appropriate Medical Device Directive. In some instances, a clinical investigation will be required. The MHRA website (listed above) provides guidance on this issue.
Small Business Research Initiative (SBRI): The new SBRI is a cross-government programme for the procurement of technology development projects, including the demonstration and evaluation of new technologies. DH has run a pilot SBRI competition in Healthcare Associated Infections in conjunction with the Technology Strategy Board. The benefit to the Department and the NHS is to make new developments available faster and more effectively. National Institute for Health and Clinical Excellence (NICE) NICE (www.nice.org.uk) is responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health. Its activities include:
Technology appraisals – Recommendations on the use of new and existing medicines and treatments within the NHS, based upon a review of clinical and economic evidence Interventional procedure guidance – Many of the procedures that NICE investigates are new, but it also looks at more established procedures if there is uncertainty about their safety or how well they work
NHS National Innovation Centre (NIC): NIC determines the need for innovative products, particularly in the development stage, and speeds up the development and adoption of those that deliver the best results for patients. It provides a point of entry to innovators of healthcare technology via its website and through a web-based assessment process. By considering ideas and products at every stage, it can direct them to the most.
ACTION NEEDED Pctl has been trying to get in contact with the government to make them aware of our machine & what it can do We can help with & in our numbers send them copies of the DD that’s been posted
This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)
Info they’ll need: PODCAST LINK click Click in search....Pctl
This is who we can contact in government to make them aware of our machine.
point of entry for the submission of market research packages and meeting requests from interested stakeholders. The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought. At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed. Ideal technologies and products would (but are not required to) be: * - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities * - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability * - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)
Would you like to meet with a federal agency regarding a product that you are developing for COVID-19? If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.
Paradigm Convergence Technologies Corporation Summarized Due Diligence Sheet for Investing [color=red]
ACTION NEEDEDPctl has been trying to get in contact with the government to make them aware of our machine & what it can do We can help with & in our numbers send them copies of the DD that’s been
This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)
This is who we can contact in government to make them aware of our machine.
point of entry for the submission of market research packages and meeting requests from interested stakeholders. The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought. At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed. Ideal technologies and products would (but are not required to) be: * - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities * - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability * - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)
Would you like to meet with a federal agency regarding a product that you are developing for COVID-19? If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.
Company Site: para-con.com Twitter: @PCTL2020 Investor Relations Chesapeake Group - Get on the email list for news info@chesapeakegp.com
About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.
Mission: Infectious Disease and Contamination Control
About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.
The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.
---FINANCIAL INFO---
Filings: LINK
Current info as of 3/9/20 Authorized- 1,000,000,000 Outstanding- 511,315,300 Restricted- 35,139,690
Standard Registrar and Transfer Company 440 East 400 South, Suite 200 Salt Lake City, UT 84111 Phone: 801-571-8844 or 801-596-2150 www.standardtransferco.com Amy Merrill Email: amy@standardregistrar.com
---CURRENT CLIENT LIST---
1: Morgan Stanley Presbyterian Children’s Hospital. (3959 Broadway At, W 165 St, New York NY 10032)
2: Mount Sinai South Nassau Hospital (1 Healthy Way, Oceanside NY 11572)
3: Carson Tahoe Regional Medical Center (1600 Medical Pkwy, Carson City NV 89703)
4: SUNY Downstate Medical Center (450 Clarkson Ave, Brooklyn NY 11203)
6: Memorial Sloan Kettering Cancer Center ??? Maybe (1275 York Avenue New York, NY 10065)
7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial) (University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH) (University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)
8: New York Presbyterian Columbia Hospital (Ranked Top 5 in the Nation) (622 W 168th St, New York NY 10032) ---VP recently endorsed in a LinkedIn post---
9: New York Hospital -- as per PR Release (labeled #1 below)
---PR & RELATED INFORMATION---
1. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK
2. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK
3. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)
4. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK
5. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK
6. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK
7. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK
8. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)
9. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR
10. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK
11. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK
12. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK
13. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK
14. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK
15. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK
16. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK
17. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK
18. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK
3rd Quarter 10Q In final review with auditors & SEC Attorneys Expected to be completed in up to 3 weeks (updated per IR email--- expected in the next week)
10K Expected to be filed by April 13th
Convertible Notes "very active negotiations" to come to a resolve by time of 10K filing (April 13th)
No material change is O/S in months
very actively negotiating financing with negligible, if any, dissolution No anticipation of R/S
---Growth of about 400% in 2019--- on target to grow exponentially in 2020
G&A down significantly company become more efficicent, losses narrowed significantly down around 75% from 2018
---Currently Doing---
PCT UK joint venture partner Trial ongoing: Universities as well as hospitals involved to verify U.S. results "unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"
"Preliminary discussions between PCT UK and National Healthcare system of the UK"
---Markets--- Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities
Secondarily - Oil & Gas, remediation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)
Recently - Cannabis Industry - purveyor of service "Happy to discover our product greatly mitigates or totally eliminates the 3 major problems they are having"
---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20) 8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"
Endorsement from VP of MY Presbyterian [Suppressed Image]
Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:
Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).
In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a comprehensive portfolio of COVID-19 countermeasures. See below.
(For my privacy, I did redact my information on the image)
Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services
[Suppressed Image]
Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services
UPDATED DUE DILIGENCE 3-17 - RESEARCH NOW Below is a good portion of the DD done here, by myself and others. Do YOURS now! (Also pinned on top of board)
Paradigm Convergence Technologies Corporation Summarized Due Diligence Sheet for Investing
---GENERAL INFORMATION---
Company Site: para-con.com Twitter: @PCTL2020 - (I urge you to follow them and review their posts) Investor Relations Chesapeake Group - Get on the email list for news info@chesapeakegp.com
About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.
Mission: Infectious Disease and Contamination Control
About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.
The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.
---FINANCIAL INFO---
Filings: LINK
Current info as of 3/9/20 Authorized- 1,000,000,000 Outstanding- 511,315,300 Restricted- 35,139,690
Standard Registrar and Transfer Company 440 East 400 South, Suite 200 Salt Lake City, UT 84111 Phone: 801-571-8844 or 801-596-2150 www.standardtransferco.com Amy Merrill Email: amy@standardregistrar.com
---CURRENT CLIENT LIST---
1: Morgan Stanley Presbyterian Children’s Hospital. (3959 Broadway At, W 165 St, New York NY 10032)
2: Mount Sinai South Nassau Hospital (1 Healthy Way, Oceanside NY 11572)
3: Carson Tahoe Regional Medical Center (1600 Medical Pkwy, Carson City NV 89703)
4: SUNY Downstate Medical Center (450 Clarkson Ave, Brooklyn NY 11203)
6: Memorial Sloan Kettering Cancer Center ??? Maybe (1275 York Avenue New York, NY 10065)
7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial) (University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH) (University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)
8: New York Presbyterian Columbia Hospital (Ranked Top 5 in the Nation) (622 W 168th St, New York NY 10032) ---VP recently endorsed in a LinkedIn post---
9: New York Hospital -- as per PR Release (labeled #1 below)
---PR & RELATED INFORMATION---
1. 03/18/20 - PCT LTD Receives Large Purchase Order for Recurring Sales of Fluids for Non-Medical Use and Explains Current Revenue Streams PR LINK
2. 03/16/20 - PCT LTD Interview with Stock Day Podcast (MUST LISTEN) PR LINK
3. 03/13/20 - PCT LTD Adds International Distributor and Sells High-Volume Equipment to Existing Customer as a Result of Heightened Demand PR LINK
4. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK
5. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK
6. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)
7. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK
8. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK
9. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK
10. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK
11. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)
12. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR
13. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK
14. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK
15. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK
16. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK
17. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK
18. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK
19. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK
20. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK
21. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK
3rd Quarter 10Q In final review with auditors & SEC Attorneys Expected to be completed in up to 3 weeks (updated per IR email--- expected in the next week)
10K Expected to be filed by April 13th
Convertible Notes "very active negotiations" to come to a resolve by time of 10K filing (April 13th)
No material change is O/S in months
very actively negotiating financing with negligible, if any, dissolution No anticipation of R/S
---Growth of about 400% in 2019--- on target to grow exponentially in 2020
G&A down significantly company become more efficicent, losses narrowed significantly down around 75% from 2018
---Currently Doing---
PCT UK joint venture partner Trial ongoing: Universities as well as hospitals involved to verify U.S. results "unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"
"Preliminary discussions between PCT UK and National Healthcare system of the UK"
---Markets--- Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities
Secondarily - Oil & Gas, remidiation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)
Recently - Cannabis Industry - purveyor of service "Happy to discover our product greatly mitigates or totally elimiants the 3 major problems they are having"
---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20) 8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"
Endorsement from VP of MY Presbyterian and other execs [Suppressed Image]
[Suppressed Image]
[Suppressed Image]
[Suppressed Image]
Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:
Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).
In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a. comprehensive portfolio of COVID-19 countermeasures. See below.
(For my privacy, I did redact my information on the image)
Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services
================= exactly what the EPA said
Quote:
List N includes products that meet EPA’s criteria for use against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19.
The key word here is against The EPA does not come out and say any products on these lists will kill CV-19. However I doubt the EPA would use a strong word as against in the above statement.
Quote:
Note: Inclusion on this list does not constitute an endorsement by EPA. There may be additional disinfectants that meet the criteria for use against SARS-CoV-2. EPA will update this list with additional products as needed.
It's pretty obvious this disclaimer is stating the EPA does not endorse as in recommend any product that's listed. They do not because it would constitute marketing for that product.... The EPA also recognizes that there are other products that meet the criteria against SARS-CV-2 AKA Coronavirus. Why do they make this statement? Because there are other products that are registered with the EPA that are not on this list that meets the criteria against CV-19
Nothing hard to understand there. Here is the a pic of it below:
[Suppressed Image]
Lets move on
List N: Disinfectants for Use Against SARS-CoV-2 | Pesticide ...www.epa.gov › pesticide-registration › list-n-disinfectants-use-against-... If a product qualified for the Emerging Viral Pathogen Claim, it demonstrated efficacy against a harder-to-kill virus than the enveloped human coronavirus
From this statement we know that EXCELYTE which meets this criteria. How do we know this? We know because they are on the N list under EPA registration 92108-1. I also believe this Reg number can be used against the harder to lill Norovirus. Coronavirus is easier to kill than Norovirus. Any amount of basic DD will show that.
Below is the reg and product number for EXCELYTE [Suppressed Image]
Finally Below is the EPA reg link for EXCELYTE showing it's registered to PCT Ltd. This link is the original registration.
Pretty basic stuff is you ask me lol ============== Pics of the product - Sorry about it being sideways
[Suppressed Image]
[Suppressed Image]
[Suppressed Image]
============ PCT LTD Obtains EPA Approval for Emerging Pathogens Labeling for Use Against SARS-CoV-2, the Novel Coronavirus That Causes the Disease COVID-19 Business WireMarch 27, 2020, 9:49 AM CST
PCT LTD (OTC Pink: PCTL) ("PCTL") is pleased to announce that it has received approval for "emerging pathogens" labeling with the US EPA.
The application was filed under the guidance document "Guidance to Registrants: Process for Making Claims Against Emerging Viral Pathogens Not on EPA-Registered Disinfectant Labels." It was approved on March 26th, 2020. The guidance document provides the following information regarding different classes of viruses and their resistance to being killed by disinfectants:
EPA and the Centers for Disease Control and Prevention (CDC) recognize that certain microorganisms can be ranked with respect to their tolerance to chemical disinfectants. The Spaulding Classification model, used by CDC, tiers microorganisms in accordance with the level of resistance to being killed (inactivation) by typical disinfectant products. With this approach viruses are divided into three viral subgroups (small non-enveloped, large non-enveloped, and enveloped) based on their relative resistance to inactivation … According to this hierarchy, if an antimicrobial product can kill a small, non-enveloped virus it should be able to kill any large, non-enveloped virus or any enveloped virus. Similarly, a product that can kill a large, non-enveloped virus should be able to kill any enveloped virus.
Small, Non-Enveloped Viruses (<50 nm): These small, non-enveloped viruses can be highly resistant to inactivation by disinfection. Despite the lack of a lipid envelope, these organisms have a very resistant protein capsid…
Large, Non-Enveloped Viruses: Compared to small, non-enveloped viruses, these viruses are less resistant to inactivation by disinfection. Although they have a resistant protein capsid, their larger size (50-100nm) makes them more vulnerable than their smaller viral counterparts…
Enveloped Viruses: Enveloped viruses are the least resistant to inactivation by disinfection. The structure of these viruses includes a lipid envelope, which is easily compromised by most disinfectants. Once the lipid envelope is damaged, the integrity of the virus is compromised, thereby neutralizing its infectivity.
In addition to being "an EPA-registered, hospital/healthcare or broad-spectrum disinfectant …", in order to meet product eligibility criteria, the product "should have disinfectant efficacy claims against at least one of the following viral pathogen groupings:
a) A product should be approved by EPA to inactivate at least one large or one small non-enveloped virus to be eligible for use against an enveloped emerging viral pathogen.
b) A product should be approved by EPA to inactivate at least one small, non-enveloped virus to be eligible for use against a large, non-enveloped emerging viral pathogen.
c) A product should be approved by EPA to inactivate at least two small, non-enveloped viruses with each from a different viral family to be eligible for use against a small, non-enveloped emerging viral pathogen.
This approach, where disinfectant products registered for use against viral pathogens in one category of the Spaulding Classification model can be presumed effective against viral pathogens in less-resistant categories, is intended to serve as a conservative approach to identifying disinfectant products likely to be effective against emerging pathogens."
As a result of meeting all of the Product Eligibility Criteria, PCT LTD can now make the following statement "only through the following communication outlets: … "1-800" consumer information services, social media sites and company websites (non-label related) … [as well as] technical literature distributed exclusively to health care facilities, physicians, nurses and public health officials":
This Product meets the criteria to make claims against certain emerging viral pathogens from the following viral category[ies]:
Enveloped Viruses
Large Non-Enveloped Viruses
Small Non-Enveloped Viruses
For an emerging viral pathogen that is a/an… …follow the directions for use for the following organisms on the label: Enveloped virus Norovirus Large, non-enveloped virus Norovirus Small, non-enveloped virus Norovirus, Rhinovirus (Type 16)
Hydrolyte® has demonstrated effectiveness against viruses similar to SARS-CoV-2 virus on hard, non-porous surfaces. Therefore, Hydrolyte® can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/community/home/cleaning-disinfection.html for additional information.
COVID-19 is caused by SARS-CoV-2 virus. Hydrolyte® kills similar viruses and therefore can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/community/home/cleaning-disinfection.html for additional information.
"We are very pleased to receive approval for an "emerging pathogens" claim on our product label," says CEO Gary Grieco. "It represents an important step for us as a business and in helping to control the spread of infectious disease as a whole. Additionally, we are now prequalified for future emerging pathogens of any virus classification."
Due to the ongoing coronavirus pandemic, PCT LTD has seen an increased number of inquiries from existing clients, sub-registrants, and distributors; in addition to new and prospective customers. The company recently announced that they had temporarily shifted their focus towards producing mass quantities of disinfecting fluids to meet growing demand.
"Fluid sales have been tremendous for us," says PCT Ltd CEO Gary Grieco. "To put it simply, we are routinely shipping fluids out at rapid pace and into the hands of trained professionals where our product can be put to good use fighting the spread of infectious disease in our communities. We are limited only by our capacity to produce the fluids, but we expect to double our production capacity by April 1st."
Additional News and Corporate Updates:
PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL.
About PCT LTD:
PCT LTD ("PCTL") focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting, cleaning and tracking technologies. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, "PCTL" aspires to and is actively engaged in preparations for up-listing its common stock to a national securities exchange. The Company established entry into its target markets with commercially viable products in the United States and now continues to gain market share in the U.S. and U.K.
Forward-Looking Statements:
This press release contains "forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."
Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: the impact of having met the EPA Criteria for use Against SARS-CoV-2, actual sales derived by the Company; the transition to producing large quantities of fluids; PCTL's and its subsidiary's business prospects; PCTL's ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCTL to execute its business plan; any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements PCTL makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the SEC. PCTL undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Gary Grieco, CEO and Chairman, PCT LTD (843) 390-7900 Office (843) 390-2347 Fax www.para-con.com www.pctcorphealth.com www.survivalyte.com
Brokers and Analysts: Chesapeake Group +1-410-825-3930 info@chesapeakegp.com ==================================================================================================================. CANADA INFO & LINKS BokehRebl Tuesday, 03/31/20 10:29:25 PM Re: Long term post# 78282 ? 0 Post # 78283 of 78339
Here’s THE list I put together of all relevant contact in the US and Canadien Government, Feel free to add more!
Louisiana Alexander Billioux, MD, DPhil [Bio] Assistant Secretary of Health Alexander.Billioux@LA.GOV
Maine Nirav Shah, MD, JD* Director, Maine Center for Disease Control and Prevention Nirav.Shah@Maine.Gov
Maryland Robert Neall Secretary of Health Frances B. Phillips, RN, MHA [Bio] Deputy Secretary for Public Health Services S/THO Designee robert.neall@maryland.gov
Michigan Joneigh Khaldun, MD, MPH, FACEP [Bio] Chief Deputy Director for Health and CME khaldunj@michigan.gov
Minnesota Jan Malcolm [Bio] Health Commissioner jan.malcolm@state.mn.us
Mississippi Thomas Dobbs, MD, MPH* State Health Officer thomas.dobbs@msdh.ms.gov
Missouri Randall W. Williams, MD, FACOG [Bio] Director randall.williams@health.mo.gov
Montana Sheila Hogan Director Gregory Holzman, MD [Bio] Chief Medical Officer S/THO Designee gHolzman@mt.gov
Nebraska Dannette Smith, MSW * Chief Executive Officer, Nebraska Department of Health & Human Services Gary Anthone, MD Chief Medical Officer and Director, Division of Public Health S/THO Designee Dannette.Smith@nebraska.gov
Nevada Lisa Sherych, MBA* Administrator lsherych@adsd.nv.gov
New Hampshire Lisa Morris, MSSW [Bio] Director, Division of Public Health Service lisa.morris@dhhs.nh.gov
New Jersey Judith Persichilli RN, BSN, MA* Commissioner of Health Judith.Pershichilli@doh.nj.gov
New York Howard Zucker, MD, JD [Bio] Commissioner of Health howard.zucker@health.ny.gov
North Carolina Mark Benton [Bio] Assistant Secretary for Public Health mark.benton@dhhs.nc.gov
North Dakota Mylynn K. Tufte, MBA, MSIM, RN [Bio] State Health Officer mylynntufte@nd.gov
Ohio Amy Acton, MD, MPH [Bio] Director of Health DirectorAmyActon@odh.ohio.gov
Oklahoma Gary Cox, JD* Commissioner of Health GaryC@health.ok.gov
Oregon Lillian M. Shirley, BSN, MPH, MPA [Bio] Public Health Director lillian.shirley@state.or.us
Pennsylvania Rachel Levine, MD [Bio] Secretary of Health ralevine@pa.gov
Puerto Rico Rafael Rodriguez Mercado, MD, FACS, FAANS Secretary of Health Catherine De La Cruz-Duran* S/THO Designee drrafael.rodriguez@salud.pr.gov
Rhode Island Nicole Alexander-Scott, MD, MPH [Bio] Director nicole.alexanderscott@health.ri.gov
South Carolina Richard Toomey, MHA, DHA [Bio] Director, South Carolina Department of Health and Environmental Control Rick.Toomey@dhec.sc.gov
South Dakota Kim Malsam-Rysdon [Bio] Secretary kim.malsam-rysdon@state.sd.us
Tennessee Lisa Piercey MD, MBA, FAAP [Bio] Commissioner tn.health@tn.gov
Texas John Hellerstedt, MD [Bio] Commissioner john.hellerstedt@dshs.texas.gov
Utah Joseph Miner, MD [Bio] Executive Director joeminer@utah.gov
Vermont Mark Levine, MD [Bio] Commissioner of Health mark.levine@vermont.gov
Virginia M. Norman Oliver, MD, MA [Bio] State Health Commissioner norm.oliver@vdh.virginia.gov
Washington John M. Wiesman, DrPH, MPH [Bio] Secretary of Health secretary@doh.wa.gov
West Virginia Cathy Slemp, MD, MPH [Bio] Commissioner and State Health Officer catherine.slemp@wv.gov
Wisconsin Jeanne Ayers, RN, MPH [Bio] Administrator, Division of Public Health Jeanne.Ayers@dhs.wisconsin.gov
Wyoming Alexia Harrist, MD, PhD [Bio] State Health Officer alexia.harrist1@wyo.gov —————————————
davidsan Wednesday, April 1, 2020 4:57:18 PM Re: None Post # 78774 of 78834 Can PCTL's fluid turn sour crude oil into sweet?
I vaguely remember this was something said in discussing why that large unnamed oil&gas company was so interested in setting up the customized trial they are doing. I remember clearly that it helped make the liquid involved in fracking much more environmentally friendly, much more green, with a more pure and less costly product, something to that effect. There was some big reason why that oil&gas company was so excited about it. If the oil&gas industry incorporates this into their standard processes, with the sheer volume of this fluid they will need every day, that will be HUGE, just that one piece of all this alone. Somewhere in there I thought I remembered that in the process it helped turn sour crude into sweet, just don't recall how specific that point was.
Anyone here remember?
This is so much more than just hospitals and spraying to kill the coronavirus. The agricultural/cannabis industry and oil&gas industry customized trials are going on as well.
And, of course, the UK trials are about to hit (The UK hospital trial already completed, and the 2 university studies are supposed to complete the end of March to first week of April, meaning anytime now). Just waiting on results and orders, both expected to be very favorable.
Hypochlorous Acid Market Demand Would Increase Rapidly Hypochlorous Acid Market: Excellent Microbial and Oxidizing Properties Hypochlorous acid is a weak acid formed by dissolving chlorine in water. It possesses excellent microbial and oxidizing properties. It is used as a disinfectant agent in medical, water treatment, and food additives in food & beverages industry. Sodium hypochlorite and calcium hypochlorite are the two types of hypochlorous acid. Sodium hypochlorite is a widely consumed hypochlorous acid. Sodium hypochlorite can be easily stored and transported. It is more effective than chlorine gas in various applications. Read report Overview@ https://www.transparencymarketresearch.com/hypochlorous-acid-market.html Hypochlorous acid is employed in various end-user industries such as water treatment, wound management, food & beverages, oil & gas, and personal care. Demand for hypochlorous acid in the wound management segment is projected to rise significantly in the near future. Hypochlorous acid acts as an excellent disinfectant in wound healing applications. It accelerates the healing process of any wound and other infections such as eye infection, ear infection, etc. Hypochlorous acid has excellent disinfectant properties, which help destroy pathogens, bacteria, and fungi. Request PDF Brochure@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=68783 Key drivers of Hypochlorous Acid market Rise in demand for oxidizing and disinfecting agents in order to provide quality water is driving the global hypochlorous acid market. Hypochlorous acid is highly cost effective. It is non-toxic to humans and animals. Therefore, it is highly preferred in the water treatment industry. Rise in usage of hypochlorous acid in sterilizing bacterial infection by drying out blood cells is boosting its demand in the medical industry. Hypochlorous acid is also used as an active sanitizing agent in swimming pools and skin cleansing agent in cosmetic applications. It is used in the manufacture of calcium hypochlorite (Ca(OCl)2) and sodium hypochlorite (NaOCl), which are further used in the manufacture of disinfectants, bleaches, and deodorants. Food & Beverage Industry and Wound Management to offer attractive opportunities Increase in usage of hypochlorous acid in the food & beverages industry is estimated to provide lucrative opportunities to manufacturers of hypochlorous acid in the near future. Hypochlorous acid is used for cleaning food processing equipment and dish washers. It is also employed as food additive in processing poultry products and seafood products. Hypochlorous acid is gaining momentum as a potential wound care agent in the pharmaceutical industry. It is a highly effective wound irrigation solution, which is entirely safe for human tissues. It aids in elimination of unpleasant wound odor and removes bacteria from wound surface. Hypochlorous Acid may form Explosive Gas in Concentrated Form likely to Restrain Market Hypochlorous acid is highly dangerous and can form explosive gas if used in concentrated form. This is anticipated to restrain the market during the forecast period. When exposed to air, it disintegrates and causes nausea, abdomen pain, etc. If released in water bodies, hypochlorous acid may harm aquatic animals, thereby adversely affecting biodiversity. These factors are estimated to restrain the demand for hypochlorous acid during the forecast period. Stuck in a neck-to-neck competition with other brands? Request a custom report on competition on Hypochlorous Acid Market here Asia Pacific Expected to Hold Leading Share in the Global Hypochlorous Acid Market In terms of region, the demand for hypochlorous acid can be split across five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of consumption, Asia Pacific dominated the global hypochlorous acid market in 2018. Developing economies such as China, India, Vietnam, and Indonesia are the leading consumers of hypochlorous acid in Asia Pacific. Rapid industrialization and increase in demand for sodium hypochlorite in chemical, agriculture, and pharmaceutical industries are anticipated to fuel the hypochlorous acid market during the forecast period. Demand for hypochlorous acid in countries in Europe such as Germany, France, and the U.K. is projected to increase during the forecast period primarily due to the rise in demand for sodium and calcium hypochlorite in the food & beverages industry in the region. The U.S. is the leading consumer of hypochlorous acid in North America. Increase in demand for hypochlorous acid in industrial applications such as cooling water treatment is propelling the market in the U.S. Latin America and Middle East & Africa are highly dependent on hypochlorous acid import. This is likely to hamper the sales of hypochlorous acid in these regions. However, production capacity expansion by various manufacturers in Brazil, Mexico, and GCC is expected to augment the demand for hypochlorous acid in Latin America and Middle East & Africa during the forecast period. Key Players in Hypochlorous Acid Market: New product launches and mergers & acquisitions are the key strategies adopted by top players operating in the market. For instance, in 2018, URGO Medical, a leading player in wound care products, entered into an asset purchasing agreement with REALM Therapeutics, a biopharmaceutical company based in the U.S. REALM Therapeutics engages in research activities to discover new hypochlorous acid based treatments for atopic dermatitis and allergic conjunctivitis. This acquisition is expected to help URGO Medical become the leading player in advanced wound care business across the globe. Key players operating in the global hypochlorous acid market include Lenntech B.V. BASF SE Arkema S.A. Lonza. Inovyn Chlorvinyls Limited Olin Corporation Nouryon (Previously under Akzo Nobel N.V.'s coating division) Occidental Petroleum Corporation Kuehne Company AGC Chemicals Surpass Chemical Company, Inc. Westlake Chemical Corporation Clorox Company Tianjin Ruifuxin Chemical Tosoh Corporation Aditya Birla Chemicals Aqualution Systems Ltd Ultrapure HOCL (Pty) Ltd Others
=================== Friday, April 3, 2020 10:10:28 AM Cherry Re: None Post # 80097 of 80187 WHY YOU WANT TO BUY ALL THE PCTL YOU CAN
Right now, IMO, before PCT LTD (ticker PCTL) announces the UK hospital results which might potentially lead to 600+ hospital installations in the UK, before the March 2020 revenues from increased fluid sales are known, before the scientific data on treating disease/mold/fungi in the citrus & cannabis industries is announced, before results from the oil & gas industry testing, and before the delayed 2019 Q3 of which will contain outdated information from over 6 months ago-
People reading here may have read and seen, in bits and pieces, all these things below.
How anyone interprets & verifies anything, and researches further, is up to them. Nothing here is advice.
Since late 2019: More hospitals, More distribution, More geographic regions, More production capacity, More sales of the fluid itself & increasing dramatically, EPA approved on List N to disinfect surfaces for NCOV-19-SARS-2, Existing clients are buying more systems or extending their contracts,
=============== Tuesday, 04/07/20 11:13:24 AM Re: Patience 1 post# 81708 0.005 Post # 81730 of 82300
Quote:
NEWS OUT!! 4/7/20, 9:55 AM LITTLE RIVER, S.C.--(BUSINESS WIRE)
PCT LTD (OTC Pink: PCTL) ("PCTL") is excited to announce they have increased production capacity at their Little River, South Carolina facility.
Updating an earlier release (March 25th), the South Carolina facility is now capable of producing up to 10,000 gallons of fluids per day. A marked increase over earlier capabilities. The company is now better positioned to meet the growing demand for its Hypochlorous Acid-based disinfecting fluids.
“Our team has been working around the clock over the last several weeks to make this happen,” says Stuart Emmons, PCTL Executive VP of Engineering and R & D. “The South Carolina facility is now better positioned to fulfill the daily orders we have been receiving.”
Due in part to the ongoing coronavirus pandemic, the company has seen an exponential increase in sales and inquiries from current and prospective customers. Late last month the company shifted its short-term focus towards fluid production and sales to meet increasing demand.
“It’s supply and demand,” according to PCTL CEO Gary Grieco. “The demand is there and now so is the supply. We needed to shift our focus towards where we can have the most impact and do the most good for our customers and the communities they serve. At the same time, this presents an opportunity for us to elevate our profile, grow our business, and showcase how effective our products can be in the ongoing fight against the spread of infectious disease.”
The company has also been hiring additional support staff to support growing business operations. Most recently, the company engaged Joseph Tippmann, graduate of The University of Michigan’s Industrial Design and Architecture program, as a new design engineer. Tippmann joined the company on a contract basis initially and has spent the past two weeks performing design updates on Annihilyzer and Hydrolyte Rack systems in addition to helping design a more modular system for easier assembly.
Tippmann is also a co-owner of Werks Manufacturing, a Fort Wayne, Indiana based manufacturing company which PCTL engages for the purpose of manufacturing and assembling parts for use in the company’s Annihilyzer® Infection Control System and other systems.
Werks Manufacturing is expanding their operation and will increase parts and assembly production to meet PCTL’s growing demand. In addition, Werks will also serve as a fluid depot for PCTL’s clients in the northern Midwest part of the United States. Werks will initially be capable of producing up to 4,000 gallons per day of disinfecting fluids, including Hydrolyte®, for sale and use by PCTL to clients in Detroit, Chicago, and throughout the region. This fluid production capacity can be increased as needed to serve growing demand.
“We are continuing our rapid growth plans,” says Grieco. “Through strategic partnerships, distribution agreements, and more, we are gaining market share, increasing revenue at a rapid pace, and growing our business both quickly and efficiently.”
Additional News and Corporate Updates:
PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL. ====================
Wednesday, April 8, 2020 1:22:30 PM Beer money Re: None Post # 82319 of 82350 Yes Gary Grieco, PCTL CEO, stated, "As a result of the capabilities and benefits of our products, many companies and municipalities across a variety of industries and geographic locations are engaging in intense discussions with PCT LTD."
PCTL "The 800 pound gorilla, Corona-virus, that has opened up a huge opportunity for us and I can not say any more than that we have been contacted by, and are actively negotiating to address the problem with both companies and government officials and I can not say more than that."
In addition, Grieco further commented, "All of our hospital customers using our infection control system and disinfectant are utilizing the systems as a front-line defense throughout their facilities, including in all public area such as restrooms, lobbies, waiting rooms, elevators, corridors, cafeterias, etc. all throughout the day and night and in the presence of patients, staff and visitors."
============ Thursday, April 9, 2020 10:01:52 AM Re: None Post # 82599 of 82789 Hypochlorous Acid Okay For Easter Eggs Hypochlorous acid is cleared by the FDA for use on meat, poultry, fish & seafood, fruits & vegetables and shell eggs as a no-rinse sanitizer. FCN 1811 is a Food Contact Notification (FCN) from the FDA for using electrolytically generated hypochlorous acid as an antimicrobial agent in an aqueous solution in the production and preparation of whole or cut meat and poultry; processed and preformed meat and poultry; fish and seafood; fruits and vegetables; and shell eggs. To read more about food contact notification 1811, visit the FDA website in the link below. https://www.hypochlorousacid.com/regulation [Suppressed Image]
================== Thursday, April 9, 2020 10:35:37 AM Re: None Post # 82670 of 82807 Why the NHS and Private Clinics Should Look Further than Alcohol-Based Sanitisers The CoViD-19 pandemic has brought alcohol to the fore; whether it is the amount the British public is consuming to get through self-isolation or the level required in hand sanitiser to make it effective, the news stories are everywhere. Many of these revolving around the shortage of traditional alcohol-based hand sanitisers and how prices are soaring. With this being the case, why then don’t the NHS and other health care facilities look elsewhere? Is there no other option? In fact, there is another option which is rapidly emerging as the new go-to sanitiser during the CoViD-19 pandemic; Hypochlorous Acid (HOCl). What is Hypochlorous Acid? HOCI is generated when white blood cells attack harmful bacteria and is harmless to the human body. In December 2019 Optometry Times published an article on HOCl and they explain it much better than I can… “HOCl is a weak acid that occurs naturally in our body. Neutrophils are white blood cells that are the first to arrive on site when an invading pathogen is detected. Neutrophils will chase down and engulf the pathogen through phagocytosis. Upon contact, neutrophils release a burst of bactericidal chemicals including its most powerful oxidizing agent, HOCl. This kills the pathogen by tearing down the cell membranes and proteins”. Optometry Times called HOCl “the perfect weapon to fight germs. It hits hard against pathogens like Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeroginosa. Yet this powerful weapon is 100 percent safe for humans, chemical free, non-toxic and all-natural”. Due to these attributes HOCl is being widely used in South Korea in their battle against CoViD-19, disinfecting everything from food to people to hospital wards and their mass transit systems. Looking at the way in which they have taken control of the spread of the virus it is clear to see that HOCl can also help the United Kingdom to gain the upper hand in this struggle. https://www.belle.org.uk/news-1/2020/4/2/why-the-nhs-and-private-clinics-should-look-to-hypochlorous-acid-rather-than-alcohol-based-sanitisers
=============
beer $money ?
Sunday, April 12, 2020 8:04:27 PM Re: BIGBUCKS post# 83703
Post # 83709 of 83745 Alex Guttman Author> Huge interest being developed on LinkedIN VP marketing and Research at Ace Janitorial, Sales Mgr Escalator Cleaning company, Senior VP HAI Consultants
Randy Stiles can't mention names without permission but I can say that most of the major healthcare systems in NYC are now using our system
Randy Stiles +Executive Account Manager at Paylidify
Jon Pickett, MBA is this being used at all Memorial Healthcare Locations? The feedback on the system has been great.
Jody Read CEO at PCT Health, PCT LTD
Glad to see that the efforts of the entire team at ACE and PCT to bring this system to market has been a success and we are looking forward to placing these systems into every hospital, surgical center, nursing homes, and long-term care facilities!
Good am Mr Jody.could I represent your company in Dubai.? Tnx
Fritz Oehler Executive Director at Sprenger Health Care Systems Looks like this product could be an answer to many infection control issues in our industry.
Sunday, April 12, 2020 8:53:14 PM Re: BIGBUCKS post# 83629
Post # 83715 of 83745 Some additional DD. The full section in that recent PCTL release includes: Quote:
The company has also been hiring additional support staff to support growing business operations. Most recently, the company engaged Joseph Tippmann, graduate of The University of Michigan’s Industrial Design and Architecture program, as a new design engineer. Tippmann joined the company on a contract basis initially and has spent the past two weeks performing design updates on Annihilyzer and Hydrolyte Rack systems in addition to helping design a more modular system for easier assembly. Tippmann is also a co-owner of Werks Manufacturing, a Fort Wayne, Indiana based manufacturing company which PCTL engages for the purpose of manufacturing and assembling parts for use in the company’s Annihilyzer® Infection Control System and other systems. Werks Manufacturing is expanding their operation and will increase parts and assembly production to meet PCTL’s growing demand. In addition, Werks will also serve as a fluid depot for PCTL’s clients in the northern Midwest part of the United States. Werks will initially be capable of producing up to 4,000 gallons per day of disinfecting fluids, including Hydrolyte®, for sale and use by PCTL to clients in Detroit, Chicago, and throughout the region. This fluid production capacity can be increased as needed to serve growing demand.
I could not find much on google in regards to Joseph Tippmann. I did find Werks Manufacturing Inc. = http://werksmfg.com ;;... but ... website is “under construction”. It appears to be located at 2300 Meyer Road Fort Wayne, IN 46803. It appears the phone number might be (260) 428-2698. Also at this address appears to be: Advanced Media Integration LLC = Video production service = Vincent P Tippmann. same phone number?
I did also find Vincent P. Tippmann at this website: https://vptag.com/ Tippmann Affiliated Group is a family owned organization with a diversified group of business segments throughout North America and around the world. Approaching a half-century in business, Tippmann Affiliated Group businesses hold 17 patents and numerous product and service awards in various industries, including Automotive, Food Service, Refrigeration, Medical Device and Transportation. As it stands today, Tippmann Affiliated Group remains a family owned organization with a diversified group of business segments throughout North America and around the world. Headquartered in Fort Wayne, IN, Tippmann Affiliated Group operates its main campus on 75 acres and 810,000 sq/ft. of manufacturing and office space. 4410 New Haven Ave Fort Wayne, IN 46803. Phone:(260) 428-2500. It appears that 2300 Meyer Road Fort Wayne, IN 46803 is immediately adjacent to 4410 New Haven Ave Fort Wayne, IN 46803. Father & son? Could Vincent Tippman be the co-owner of Werks Manufacturing (together with Joseph Tippmann?
=====================
Ronin Wednesday, 04/15/20 10:42:51 AM Re: TKane post# 86153 Post # 86171 of 86190
News hit DOW JONES and BUSINESS wire! Lots of eyes on this now!
Evaluate Wednesday, April 15, 2020 3:12:04 PM Re: Evaluate post# 86473 Post # 86479 of 86491 https://pureandclean.us/disinfectant-sanitizer-gallon/ It appears that Pure & Clean is a distributor for PCT's HOCl, at 460 PPM, since their web page shows it is a distributor of EPA Reg. No. 92108-1. Only available in the following states: Florida, Kansas Maryland, Missouri, Nevada, Oklahoma and Texas. For all other states, please order the Surface Cleaner Pro products: https://pureandclean.us/surface-cleanser-pro/ Pure&Clean Disinfectant/Sanitizer? 460 ppm HOCl. This is a New Generation Disinfectant formulated using Hypochlorous Acid (HOCl) that cleans, deodorizes, and disinfects. As a distributor of EPA Reg. No. 92108-1, the product pure&clean™ (EPA Reg. No. 92108-1-88098) is included on the list of products approved by the US
=====================
BIGBUCKS Wednesday, April 15, 2020 3:09:42 PM Re: None Post # 86478 of 86491 PCT LTD Reports Q3 2019 Financials; Revenue Increases 435%, Operating Expenses Decrease
At 0’37: it shows that the “Annihilyzer is “Presented By: Annihilare and Paradigm Convergence Technology Corp” I was surprised to see this. Question: Does Annihilare also share in the revenues/profits of selling/leasing Annihilyzers?
=========== BRITT2575 ? Friday, 04/17/20 12:41:50 AM Re: None ? 0 Post # 88648 of 88658
PCT EUROPE LTD SIGNS DISTRIBUTION AGREEMENT WITH UK NHS COMPANY, RECEIVES ADDITIONAL NYC HOSPITAL ORDER April 17 2020 - 12:08AM InvestorsHub NewsWire Print PCT EUROPE LTD SIGNS DISTRIBUTION AGREEMENT WITH UK NHS COMPANY, RECEIVES ADDITIONAL NYC HOSPITAL ORDER
Little River, SC -- April 17, 2020 -- InvestorsHub NewsWire -- PCT LTD (OTC Pink: PCTL) is pleased to announce new growth and expansion activities in the UK and NYC. PCT Europe Ltd, the UK-based partner of PCTL is pleased to announce they have signed an exclusive trading partnership/distributor agreement with an NHS (U.K. National Health Service) company.
In tandem with PCT Europe Ltd, the UK NHS company will introduce PCT technology to each NHS Hospital Trust with the intention of them rolling out PCT's unique technology and system throughout the health services 233 Trusts comprising over 600 hospitals. In addition, approximately 14,000 Care Homes in the U.K. will also be introduced to PCT's technology. A steady flow of orders is expected to commence throughout the remainder of 2020 and into 2021.
The first PCT system has now been installed in a large NHS hospital in the north of England. This system is expected to enter clinical service early in May once the final series of biological tests of the PCT hospital disinfectant solution have been completed. Results of these tests have so far demonstrated that the PCT disinfectant has met or exceeded its ability to kill the range of pathogens previously achieved during EPA tests in the United States.
"We couldn't be happier with the results thus far in our UK trials and are delighted with the progress our UK partner is making. This arrangement will introduce our system to thousands of hospitals and healthcare facilities," says PCTL CEO Gary Grieco. "At the same time, the reality of the current healthcare crisis both domestically and abroad is sobering. We're thrilled to be able to grow our business but nevertheless remain focused on our core mission which from day one has always been helping people."
The company continues to expand domestically as well. Following an earlier release dated April 14th, the company is also announcing an additional purchase order for PCT Corp.'s Annihilyzer® Infection Control Systems in New York City.
The order comes from a large NYC hospital with a current bed count in excess of 2,500. Installation will be made in coordination with PCT Corp's primary healthcare distributor, ACE Janitorial Services.
"With three PO's for our infection control system this week and more on the way, we continue to make strides both in growing our business as well as our goal of helping our clients fight the spread of infectious diseases," says Grieco. "We are on pace for unprecedented and record growth in all areas of our business."
Additional News and Corporate Updates:
PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL.
========================
Details for EXCELYTE VET * EPA Contract Info EPA Contact Information
PM Re: None Post # 92362 of 92385 PCTL> UK NHS is the largest single healthcare delivery organisation in the world.
SELLING TO THE NHS
SUMMARY This guide outlines the structures that exist to help companies contact and sell existing and innovative products into the NHS, a huge organisation which can appear very complex.
IN BRIEF NHS Supply Chain Procurement routes – national, regional and local contracts
Products for GP prescription
Estates – capital equipment
Innovation – new products
The NHS is the largest single healthcare delivery organisation in the world. It constitutes a major opportunity for UK medical device companies. NHS trusts can purchase products through one of five main routes:
Directly from suppliers using National Framework Contracts
From the NHS Supply Chain which provides end-to-end supply chain services incorporating procurement, logistics, e-commerce and customer and supplier support
The NHS Supply Chain is a single organisation created for the benefit of NHS trusts, hospitals and other healthcare organisations. The organisation combines the former NHS Logistics Authority, significant parts of the NHS Purchasing and Supply Agency, expertise in healthcare logistics from DHL and procurement experience from Novation.
PROCUREMENT ROUTES National contracts Tenders: Contracts for products and services valued at over £90,319 (01 Jan 2008) must be advertised in the Supplement to the daily Official Journal of the European Union (OJEU). Procurement levels change, but you can confirm the current level by visiting: http://www.ojec.com.
NHS-sid: This is the official NHS supplier information database on which companies can enter their information for free:
http://www.sid4health.nhs.uk. It rationalises the management of pre-qualification data during the procurement process and can only be fully accessed by authorised NHS personnel. Suppliers looking to compete for advertised NHS contracts must still submit applications in the required format. Any supplier is free to register its services on NHS-sid. The information published is made freely available to NHS users. Registering on this system does not imply that a supplier has any special or ‘approved’ status. Regional contracts Collaborative organisations: Most NHS trusts are now partners in ‘collaborative procurement organisations’ where, normally on a regional basis, they can share information and resources to achieve economies of scale.
Local contracts Individual trust contracts: Local contracts are often managed by a trust’s supplies department. Its approach to suppliers will vary according to the value, size and complexity of its requirements. DH has set down procurement guidelines indicating that for contracts valued below £3,000 a trust should ask for telephone quotes; for contracts valued between £3,000 and £10,000, it should request a minimum of three written quotes; for contracts valued above £10,000, a minimum of three formal written tenders should be sought. Actual interpretations of these guidelines vary from trust to trust.
PRODUCTS FOR GP PRESCRIPTION
Suppliers wishing to list their products under the Drug Tariff for prescription by GPs or nurses must seek approval from the NHS Business Service Authority (NHSBSA). These will usually be products for self-administration, possibly with a carer’s help, and will normally fall into the following categories: dressings, bandage and associated appliances, incontinence appliances, stoma appliances, and chemical reagents. If the NHSBSA grant approval, the cost, either comparatively with other similar products, or, if it is a new treatment regime, by comparison with alternatives, will be reimbursed. You can access the application form at: www.nhsbsa.nhs.uk.
ESTATES – CAPITAL EQUIPMENT
DH uses two major Public and Private Partnerships (PPPs) to deliver its NHS Plan: the Private Finance Initiative (PFI) and NHS Local Improvement Finance Trust (LIFT). The NHS ProCure 21 Framework brings the NHS and the construction industry together for new-build projects. You can find information on PPPs and associated procurement policies at: www.dh.gov.uk.
INNOVATION – NEW PRODUCTS
The procurement routes above apply to established products. If you are a supplier of innovative products, you should be aware of the organisations involved in product approval:
The UK Medicines and Healthcare product Regulatory Agency (MHRA) This is the government agency responsible for ensuring that medicines and medical devices work and are safe.
Regulatory affairs: Medical devices can only be placed on the market in the UK/EU if they are certified safe, are of the required quality to fulfill the manufacturer’s ‘intended purpose’ and comply with the appropriate Medical Device Directive (CE marking). The MHRA audits the performance of manufacturers and notifies bodies responsible for granting CE marks. You can find more details at: www.mhra.gov.uk.
Clinical trials: The MHRA approves clinical trials/investigations and provides guidance for manufacturers. To obtain a CE mark, a manufacturer must show that the device complies with the relevant ‘Essential Requirements’ of the appropriate Medical Device Directive. In some instances, a clinical investigation will be required. The MHRA website (listed above) provides guidance on this issue.
Small Business Research Initiative (SBRI): The new SBRI is a cross-government programme for the procurement of technology development projects, including the demonstration and evaluation of new technologies. DH has run a pilot SBRI competition in Healthcare Associated Infections in conjunction with the Technology Strategy Board. The benefit to the Department and the NHS is to make new developments available faster and more effectively. National Institute for Health and Clinical Excellence (NICE) NICE (www.nice.org.uk) is responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health. Its activities include:
Technology appraisals – Recommendations on the use of new and existing medicines and treatments within the NHS, based upon a review of clinical and economic evidence Interventional procedure guidance – Many of the procedures that NICE investigates are new, but it also looks at more established procedures if there is uncertainty about their safety or how well they work
NHS National Innovation Centre (NIC): NIC determines the need for innovative products, particularly in the development stage, and speeds up the development and adoption of those that deliver the best results for patients. It provides a point of entry to innovators of healthcare technology via its website and through a web-based assessment process. By considering ideas and products at every stage, it can direct them to the most.